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iAbstract
Drug delivery systems (DDS) have been developed in the last decades to improve the 
pharmacological properties of free drugs by modifying their pharmacokinetic profile and 
biodistribution. Major limitations for newly developed drug molecules are the poor water 
solubility and stability, which can be addressed by DDS. These can protect the drugs from 
the potentially harsh external conditions found in the biological fluids, and improve their 
dissolution rate by different strategies, overall increasing the therapeutic activity of the 
drugs. Additionally, chemotherapeutic agents are nonspecific in nature, leading to 
deleterious off-target side effects, and poor therapeutic efficacy. Therefore, targeted therapy 
plays a very important role in cancer treatment, although not without obstacles, since DDS 
have to overcome a number of biological barriers following their intravenous 
administration, including renal clearance or opsonization-mediated phagocytosis and 
efficient extravasation to the tumor.
Mesoporous silicon (PSi) micro- and nanoparticles offer numerous benefits for 
biomedical applications, in particular for drug delivery. Along with a great biocompatibility 
and biodegradability, PSi possess mesopores (2‒50 nm), where the drugs can be easily 
loaded and confined in their amorphous state avoiding extensive crystallization, thus,
increasing their dissolution rate. However, the release of drugs from this platform is 
uncontrolled and fast, necessitating the use of strategies to tune the drug release.
In this thesis, multiple approaches were used for the design and fabrication of hybrid 
composites for drug delivery and cancer therapy, including PSi and polymer‒drug 
conjugate-based DDS produced by different modalities of the microfluidics technology and
pH-switch nanoprecipitation.
First, the loading and release of drugs with different solubility characteristics from PSi 
were investigated, and further PSi-lipid and polymer-composites were developed to control
the drug release profiles. Overall, it was achieved both a sustained release of hydrophilic 
and hydrophobic molecules loaded on the PSi and also a reduced initial ‘burst release’ from
the bare PSi particles.
Next, PSi-based nanovectors were envisaged for antitumoral applications. A smart PSi-
based hybrid nanocomposite with stealth properties was developed, consisting of a pH-
responsive polymeric structure assembled on the surface of drug-loaded PSi nanoparticles.
This nanocomposite was extremely efficient avoiding drug release from PSi under 
physiological conditions, while allowing the release of the drug upon acidification of the 
medium. Remarkably, the nanocomposites avoided extensive macrophage recognition and 
phagocytosis. 
Thereupon, a tumor targeted theranostic nanoplatform with dual pH- and magnetic-
response capacity was designed. The DDS consisted of a polymeric-drug conjugate 
nanoparticle containing an imaging agent and decorated with a tumor homing peptide for 
targeted drug delivery, which was successfully applied for intracellular triggered drug 
release.
Overall, the hybrid composites based on PSi and a polymer-drug conjugate represented
an advanced contribution to the field of drug delivery and cancer therapy, and in particular 
to the development of PSi as a platform for advanced drug delivery applications.
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11 Introduction
Drug delivery systems (DDS) have been developed in the last decades to improve the 
pharmacological properties of free drugs [1-3] by modifying their pharmacokinetic profile 
and biodistribution [4], or by acting as drug reservoirs for sustained drug release. The poor 
water solubility of drugs is one of the major problems in drug development. For instance, 
for oral administration, the dissolution rate of practically insoluble drugs may be slower 
than the gastrointestinal (GI) transit time, resulting in therapeutically unacceptable 
bioavailability [5]. Even more challenging is the intravenous (i.v.) administration of poorly 
water-soluble anticancer drugs, necessitating the application of organic solvents to dissolve 
them prior to their administration [6]. In addition, many of the newly developed drugs 
consist of peptides or other biomacromolecules, which often suffer from degradation in the 
biological fluids, thus losing their activity [7]. Drugs integrated within DDS are protected 
from potentially harsh external conditions, such as acidic pH or enzymes that may degrade 
them, and their release may be tuned by different strategies, thus increasing the 
bioavailability of the drug [8-10].
In particular, chemotherapeutic agents generally suffer from low solubility and stability,
and are nonspecific, leading to deleterious off-target side effects and poor therapeutic 
efficacy. Therefore, targeted therapy in cancer plays a very important role [11]. For this 
reason, DDS have been extensively used as a tool for nanomedicine in the treatment of solid 
tumors. Nowadays, there are a number of examples of nanomedicines in the market, such 
as Daunoxome® (liposomal daunorubicin), Doxil® (liposomal doxorubicin; DOX),
Depocyt® (liposomal cytarabine), or the recently approved Lypusu®, which represents the 
first paclitaxel-based liposomal formulation on the market. However, DDS have to 
overcome various biological barriers following their i.v. administration. The first of these is 
the renal clearance or opsonization-mediated phagocytosis by the mononuclear phagocytic 
system (MPS), which is influenced by the size and stealth properties of the DDS [12, 13].
Thereafter, the DDS have to extravasate to the tumor either passively, taking advantage of 
the leaky vasculature of the tumor angiogenic blood vessels; or actively, by targeting to the 
tumor vasculature using ligands that specifically bind to receptors expressed by the tumor-
related cells. Tumor accumulation of the NPs is, in both cases, is boosted by DDS presenting 
long blood circulation times, by increasing the chances of the NPs to contact with the 
tumoral endothelial vascular cells and undergo active or passive extravasation [14-16].
As a result of the abovementioned challenges, DDS have evolved towards high loading 
capacity of therapeutic compounds, and controlled and targeted drug release. It is, 
nonetheless, crucial that the DDS are biocompatible and biodegradable in order to avoid 
any DDS-associated toxicity. Consequently, the biocompatibility and biodegradability of 
natural lipids have been widely exploited in this respect [17, 18]. In addition, a great effort
is directed towards the development of biocompatible and biodegradable polymeric and 
inorganic materials which in turn offer great versatility for the development of advanced 
DDS [19]. These include polymers, such as polyglycolide, polylactide, polycaprolactone, 
polydioxane, poly(lactide-co-glycolide), or poly(trimethylene carbonate); and inorganic 
nanoparticles made out of silicon or calcium phosphate, among others [20, 21].
2Among the materials exploited for drug delivery applications, porous silicon (PSi)
stands out because of its many ideal characteristics in drug delivery and biomedicine [22-
24]. First, and most importantly, PSi is biocompatible and its biodegradability in biological 
fluids is well established and can be easily tuned. In addition, due to the micro- or nano-
metric dimensions and the high porosity, PSi presents a large surface area. Together with a 
great pore volume, PSi can be loaded with considerable amounts of drug molecules, 
overcoming some of the greatest challenges that DDS have to address. In addition, the 
mesopores provide PSi with some exciting characteristics. For example, highly PSi was 
found to emit visible photoluminescence upon excitation with a green or blue laser, due to 
the two-dimensional quantum size effect [25]. Another exciting characteristic about PSi is 
that the drug molecules loaded are stabilized within the confined pores by limiting their 
arrangement in crystal lattices, providing loaded molecules with different physicochemical 
properties than the ones found in the bulk. This translates into improved dissolution of 
poorly water-soluble molecules and sustained dissolution of water soluble molecules [26].
Finally, the surface chemistry of PSi can be modified, rendering the particles with different 
properties [27].
However, PSi does not allow the controlled drug delivery of payloads. Upon 
administration, the mesopores are readily accessible by the body fluids, which can displace 
the payload, resulting in off-target premature drug release and, possibly, subsequent drug
degradation, side effects, and loss of therapeutic efficacy. To overcome this hurdle, PSi 
particles decorated with a number of moieties or PSi-based hybrid composites have been
designed in order to cap the pores and obtain drug release in a sustained or triggered fashion
[28, 29]. Among the methods reported to produce lipid or polymer-based DDS, the
microfluidics technology has shown great potential [30, 31]. This technique is used to
precisely manipulate fluids in the micrometric scale in a highly reproducible way [32]. Two 
approaches are used for the fabrication of DDS by microfluidics: (1) droplet-based [32] and
(2) and mixing-based microfluidics [33, 34]. The former generally renders DDS in the 
micrometric range, while the latter is based on the nanoprecipitation principle, rendering 
DDS in the nano-range. Remarkably, the microfluidics production of DDS ensures high 
encapsulation efficiency, while enabling a precise control of the size and dispersity.
In this dissertation, different materials and methodologies were developed for the 
fabrication of advanced DDS, and their potential applications were tested in vitro. PSi was 
loaded with different drug molecules to subsequently fabricate lipid and polymer-based PSi 
micro- and nano-composites. First, single and double emulsion droplet-based microfluidics 
technology was applied for the formation of PSi-lipid composites. The drug release profiles 
from these DDS were studied in vitro to assess the sustained drug release properties. Further 
steps were given towards the in vitro evaluation of the potential of DDS for cancer 
applications. For this purpose, different designs of polymer-based DDS were explored,
aiming at accomplishing stimuli-triggered drug release, avoiding macrophage recognition,
and achieving active targeting, while attaining good biocompatibility and stability in 
biological fluids. The DDS consisted of a PSi-polymer composite produced by fast mixing-
based microfluidics, and a polymer-drug conjugate nanoparticle (NP) produced by bulk 
nanoprecipitation.
32 Review of the literature
2.1 Particulate drug delivery systems (DDS)
2.1.1 Overview and challenges
DDS have been developed in the last decades to improve the pharmacological properties of 
free drugs [2, 3]. In particular, some of the properties that might be improve by formulating 
drugs into DDS and that directly affect their bioavailability are the solubility of poorly 
water-soluble drugs and their stability in biological fluids [35]. Therefore, poorly water-
soluble molecules may be formulated into DDS, such as cyclodextrins, porous structured 
materials, or other lipid- and polymer-based supramolecular structures to improve their 
dissolution rate [36-39]. In addition, DDS may also protect the loaded drugs from potentially 
harsh external conditions, such as acidic pH or enzymes that could degrade them [8-10].
However, when loading drugs into the DDS, the potency of the drug and the loading 
capacity of the DDS have to be taken into account in such a manner that drugs with low 
potency should be formulated into DDS with high loading capacity in order to maintain a 
reasonable dose in the DDS [1]. Table 1 shows the potential problems associated with drug 
molecules and some of the solutions provided by their formulation in DDS.
Table 1. Pharmacological problems of drugs and some solutions provided by DDS. Modified with 
permission from ref. [1].
Problem Implication Effect of DDS
Poor solubility
A convenient pharmaceutical format 
is difficult to achieve, as 
hydrophobic drugs may precipitate 
in aqueous media. Toxicities are 
associated with the use of excipients 
DDS such as lipid micelles or liposomes 
provide both hydrophilic and hydrophobic
environments, enhancing drug solubility
Tissue damage on 
extravasation
Inadvertent extravasation of 
cytotoxic drugs leads to tissue 
damage
Regulated drug release from the DDS can 
reduce or eliminate tissue damage on 
accidental extravasation
Rapid breakdown 
of the drug in vivo
Loss of activity of the drug 
following administration
DDS protects the drug from premature 
degradation and functions as a sustained 
release system. Lower doses of drug are 
required
Unfavorable 
pharmacokinetics
Drug is cleared too rapidly, for 
example by the kidney, requiring 
high doses or continuous infusion
DDS can substantially alter the 
pharmacokinetics of the drug and reduce 
clearance. Rapid renal clearance of small 
molecules is avoided
Poor 
biodistribution
Drugs that have widespread 
distribution in the body can affect 
normal tissues, resulting in dose-
limiting side effects
The particulate nature of DDS lowers the 
volume of distribution and helps to reduce 
side effects in sensitive, non-target tissues
4 
 
The DDS have been classified in three generations according to their properties [4, 40]. 
The first generation of DDS are systems capable of delivering an active substance to a target 
site when implanted close to it. The second generation, smart delivery systems, consist of 
smart polymers and hydrogels and nanoparticles (NPs) capable of carrying the drug to the 
target site after administration, protecting the drug along the delivery route and passively 
accumulating at the target site. Besides zero-order controlled drug release, peptide and 
protein delivery have also been demonstrated. The third generation of DDS, in addition to 
the previously mentioned properties, present the capacity to deliver poorly water-soluble 
drugs in a disease-targeted manner [4, 40]. 
In addition, DDS are classified according to their composition and structure. Generally, 
lipids, polymers, carbon, or inorganic materials, such as metal oxides, or silicon have been 
utilized for the fabrication of particulate DDS [40] in the formulations of liposomes, lipid 
emulsions, lipid-drug complexes, micelles, polymer-drug conjugates, and inorganic NPs, 
among others (Table 2).  
Table 2. Summary of some of the particles used for drug delivery applications. Modified with 
permission from refs. [41, 42]. 
Composition Particle type Properties 
Polymer 
 Polymersome 
Micelles 
Nanospheres 
Nanocapsules 
Drug delivery 
Some biodegradable 
Lipid 
 
Liposomes 
Micelles 
Solid lipid particles 
Drug delivery 
Biocompatible 
Carrying hydrophobic 
cargos 
Inorganic 
particles, e.g. 
silicon and 
silica 
 
Spheres 
Shells 
Mesoporous 
Drug delivery 
Luminescence 
Contrast agents 
Biocompatible 
Biodegradable 
Carbon-based 
 
Carbon nanotubes 
Graphene 
Drug delivery 
Biocompatible 
 
The DDS are designed to improve the pharmacological properties of free drugs by 
modifying their pharmacokinetic profile and biodistribution [4], or by acting as drug 
reservoirs for sustained drug release [1, 43]. DDS can be configured to present prolonged 
residence time in the body, either by reducing the clearance from the bloodstream, or by 
prolonging the retention in the GI tract, eye, skin, etc. [44-46]. Moreover, the volume of 
distribution of the DDS compared to free drugs is decreased due to the limited permeation 
of particles across the biological barriers [47], meaning that the volume of distribution of 
the drug formulated into a DDS is determined by the release rate of the drug [1]. An example 
5for this pharmacological improvement is given by the PEGylated liposomal formulation of 
DOX (Doxil®). Due to the prolonged circulation time of the PEGylated liposomes, the half-
life of DOX was increased to up to 79 h, and the volume of distribution was limited to 
almost the plasma volume [48], overall rising the drug levels found in malignant effusions 
compared to free DOX [49].
DDS can be applied to different administration routes, each of them with a number of 
factors to consider and potential applications. The i.v. administration of DDS allows the 
drug to reach otherwise inaccessible sites in the body, and be rerouted away from the sites 
where the drug is toxic [40]. The blood vessels do not permit the extravasation of DDS,
except through the discontinuous capillary endothelium found in the liver, spleen, and bone 
marrow [50]. In addition, pathological conditions, such as inflammation or solid tumors,
render capillary endothelia particularly leaky, which has given place to the development of 
a number of DDS exploiting this characteristic [51, 52]. DDS administered orally, as a
general rule, cannot reach the blood circulation, and are designed to protect labile drugs 
from degradation in the GI tract and to increase the bioavailability of poorly water-soluble 
drugs by enhancing their dissolution rate, localizing the delivery of the drug, and increasing 
the residence time of the system in the GI tract, while reducing the toxic effects of drugs 
[53]. Another administration route of DDS that holds great potential is the eye. Bioadhesive 
DDS have demonstrated to be retained in the eye and penetrate through the corneal 
epithelium [54, 55]. Other administration routes, such as subcutaneous, intramuscular, and 
topical have shown greater retention times for the DDS at the administration site compared 
to free drugs [40].
Probably, the greatest challenge that DDS have to face is their access to the clinic. 
Besides purely regulatory and industrial limitations [56], some of the technological barriers 
that the DDS have to overcome are the complexity of the systems and production, the safety 
and efficacy, the cost, and the storage stability [1, 57]. In terms of expenses, although the 
cost per treatment for DDS can be higher than for the free drugs, if one sums up the expenses
related to side effects, DDS have demonstrated to be more cost-competitive than the free 
drugs [1, 58]. However, there is still much to understand about the pharmacokinetic of DDS
[59] and the safety of the novel molecules used in their manufacture. Therefore, validated 
techniques for evaluating their pharmacokinetic profile and safety have to be implemented.
In addition, the heterogeneity of complex multicomponent products must be minimized and 
controlled to ensure the reproducible manufacture at the industrial scale [57]. Despite the 
great challenge ahead, DDS have reached the market, mostly in the form of PEGylated lipid-
based DDS for monotherapy [1, 2].
2.1.2 Porous silicon (PSi)
Mesoporous silicon (PSi), consisting of a crystalline silicon (Si) structure with pores in the 
size range of 2 to 50 nm, was first reported by Uhlir in 1956. In his search for a technique 
to shape semiconductor materials, Uhlir described the electrolytic etching of Si, through 
which PSi was obtained [60]; however, it was not until 1971 when the porosity of the 
structure of PSi was described [61]. Thereafter, highly PSi wires were found to emit visible 
photoluminescence upon excitation with a green or blue laser, owed to the two-dimensional 
6quantum size effect [25]; and, later on, PSi demonstrated to be biocompatible in vitro [62],
this finding being the stepping stone for the following studies about this material as a tool 
for biomedicine, especially in the field of drug delivery.
2.1.2.1 Fabrication and surface chemistry modification of PSi
The production of PSi is commonly carried out by the electrochemical dissolution of bulk 
Si in a hydrofluoric acid (HF) based electrolyte [27, 63, 64]. For this, a Si wafer is placed 
between two HF resistant electrolyte cells, in which platinum electrodes are located on both 
sides of the Si wafer, and an electrical current is applied between them. The upper side of 
the Si substrate acts as the anode, where the oxidation and chemical etching of the Si surface 
takes place, with the subsequent dissolution of Si and formation of a PSi layer. The lower 
side of the wafer is the cathode, which is in contact with a conductive metal. Here, the proton 
reduction takes place, leading to the formation and evacuation of hydrogen (H2) [64].
Therefore, in this setup, the dissolution of Si and formation of the porous layer occurs 
exclusively at the anode.
The final characteristics of the PSi layer obtained, such as porosity, thickness, and pore 
size and shape, directly depend on the conditions of the fabrication [27], which are finely 
tuned in order to get a specific and reproducible structure. These include the voltage and 
density of the electrical current applied to the electrodes, the concentration of HF in the 
electrolyte solution, the type, doping, resistivity, and crystallographic orientation of the Si
wafer, the temperature, and the time [27].
Freshly etched PSi presents on its surface hydrophobic Si-H, Si-H2, and Si-H3 groups, 
that tend to oxidize under atmospheric conditions upon few months of storage, rendering a 
hydrophilic surface [27]. The application of native PSi for drug delivery is limited, since 
surface hydrides have been found to be strong reducing agents and incompatible with redox-
active payloads [63, 65]. For this reason, the surface of PSi is generally stabilized through 
different methods, such as oxidation, hydrosilylation, or carbonization[27].
Oxidation is one of the most common ways to stabilize the surface of PSi, because of its 
simplicity, and the biocompatibility of the oxidized surface [66]. There are different 
oxidation methods, such as anodic [67], photo [68], chemical [69], and thermal oxidation
[63]. Among them, thermal oxidation at low temperatures has been extensively used, 
through which two types of surface oxidation take place, i.e., Si-Si back-bond oxidation and 
Si-H bond oxidation, to render -OySiHx, Si-O-Si, and Si-OH surface species [70]. The PSi
obtained by this method has received the name of thermally oxidized PSi (TOPSi).
Oxidation provides stability and hydrophilicity to the surface of PSi, which are key factors 
for drug delivery applications. However, it might not be favorable for the loading of certain 
drugs or some drugs may react with the oxidized surface [71]. In addition, oxidation of the 
back-bond of Si, leads to the expansion of the structure and reduction in the pore diameter
[71]. This phenomena has been exploited in drug delivery for the oxidation-trapping post-
loading of drugs into native PSi [72].
Hydrosilylation of alkenes or alkynes on the surface of PSi [73-75], consists of the 
reaction of surface species SiHx with compounds containing C=C, C≡C, or C=O to yield Si-
C-C, Si-C=C, or Si-C-O. These modifications have been used to increase the stability of PSi 
7and to attach molecules with specific functional groups at the opposite end of the chain. 
Methodologies including, Lewis acid catalyzed, white light promoted, cathodic 
electrografting, and thermal hydrosilylation, have been applied for the hydrosilylation of 
PSi [64]. In particular, thermal hydrosilylation is a simple technique that has been used to 
produce, among others, hydrophilic derivatized undecylenic acid PSi [76].
Carbonization of the surface of PSi refers to the substitution of the Si-H bonds for Si-C
bonds, providing PSi with stability towards harsh chemical conditions and oxidation [77, 
78]. The most commonly used method is the thermal carbonization of PSi in the presence 
of acetylene. Due to the rapid diffusion of the small molecules of acetylene through the 
pores, a complete carbonization of the surface can be achieved. Depending on the 
temperature used, two types of surface chemistries are obtained. These are, Si-CH, when 
the treatment temperature is below 650 ºC, rendering thermally hydrocarbonized PSi
(THCPSi), with hydrophobic surface properties; and hydrogen-free Si-C species, when the 
treatment temperature is above 700 ºC, generating thermally carbonized PSi (TCPSi) with
hydrophilic surface properties [77, 79]. Similarly to the hydrosilylation of native PSi, the 
surface of the THCPSi NPs has been functionalized by thermal treatment of the particles in
undecylenic acid to obtain undecylenic acid modified THCPSi (UnTHCPSi). The presence 
of –COOH groups allow easy covalent attachment of other biopolymers, macromolecules, 
or fluorescent dyes, having a great impact for drug delivery applications [80].
2.1.2.2 Biocompatibility and biodegradability
The first in vitro incursion into the biocompatibility of PSi was successfully performed by 
Canham in 1995 [62]. Later, encompassing the increased interest in PSi in the field of 
biomedicine, great efforts have been dedicated to the investigation of the biocompatibility 
of this material [81-84], as well as to its fate in the body [82, 85-88]. Although in vitro
models are a good tool to understand the interactions and effects of a biomaterial over 
different cell lines, they do not account for the possible effects of the biomaterial over the 
complex systems of a human body. Therefore, in vivo studies are also required to determine 
the biosafety of a material. In this respect, in vitro and in vivo models have been applied to 
determine the biocompatibility of PSi, revealing that a number of parameters, including size 
[84], pore size [83], and surface chemistry [89] have an effect on its toxicity.
The biocompatibility of PSi for oral administration has been widely studied in vitro with 
GI-related cell models [90, 91]. For example, the toxic effects of TOPSi NPs with different 
pore sizes, between 17 and 58 nm, and amine functionalized PSi NPs incubated with a co-
culture of Caco-2/HT29-MTX cells have been evaluated [83]. The results revealed that 
increasing the pore size of TOPSi NPs might enhance the cytoxicity of the particles;
however, this was justified either by the pore size of the particles or by the different 
methodology used to produce the TOPSi NPs with different pore sizes. TOPSi NPs with 
larger pore sizes were annealed in order to increase the pore size prior to their thermal 
oxidation, which has been found to decrease the density of –OH groups on the surface, and 
that could have influenced the toxicity of the NPs. Besides, amine functionalized PSi NPs 
were more cytotoxic than TOPSi NPs with similar pore size [83].
8The biocompatibility of PSi in vivo in the rat eye has also been tested [81, 92, 93]. In
one study, hydrosilylated PSi and TOPSi with sizes between 1 and 270 μm were injected 
into the rabbit’s vitreous and observed until their total degradation in 3-4 weeks [92]. The 
authors reported no signs of toxicity in the different parts of the eye of the animals.
Moreover, chemical modification of the particles and pores’ surface by hydrosilylation or 
by thermal oxidation dramatically increased the stability and vitreous residence time of the 
particles, thus revealing the feasibility of using PSi as a long-lasting intravitreal drug-
delivery vehicle.
Recently, a study presented the toxic effects of various surface modified PSi NPs
assessed in vitro in blood immune and red blood cells (RBCs), and also in vivo, based on 
histopathological and biochemical parameters [89]. Overall, the in vitro studies showed that
the toxicity was greatly dependent on the surface charge of the PSi NPs, and to a lesser 
extent on their hydrophobicity. Thus, positively charged 3-aminopropyltriethoxysilane 
modified thermally carbonized porous silicon (APSTCPSi) or the more hydrophobic 
UnTHCPSi, showed the greatest impact on RBCs’ morphology, and APSTCPSi the greatest 
damage to the DNA, compared to TOPSi, TCPSi, and THCPSi. In vivo, the
histopathological and biochemical parameters assessed after the i.v. injection of PSi 
revealed the biosafety of TOPSi, TCPSi, and THCPSi, showing mild histological changes 
in kidney, liver, and spleen, whereas APSTCPSi and UnTHCPSi presented greater toxicity.
The biocompatibility of PSi micro- and nano-particles have also been studied for their 
application in drug delivery to the heart tissue to treat myocardial infarction [84]. THCPSi 
and TOPSi microparticles (MPs) and NPs were evaluated, showing good in vivo
biocompatibility and no alterations on the cardiac function or the hematological parameters. 
However THCPSi MPs activated inflammatory cytokines and fibrosis promoting genes. 
Thus, THCPSi and TOPSi MPs and TOPSi NPs could as well serve as vehicles for 
improving the cardiac delivery of therapeutic agents.
A further concern about the biocompatibility of any substance introduced in the body is 
its biodegradability, as well as the biocompatibility and rate of production of the degradation 
products [94]. In this respect, PSi degrades in aqueous solutions to orthosilicic acid through 
oxidative hydrolysis [95], which has been corroborated in vivo, demonstrating also to be
biocompatible [86, 96, 97] and cleared from the body through the urinary pathway [87].
Furthermore, the degradation rate of PSi directly depends on the degree of crystallinity [98],
the porosity and surface area [99], the surface chemistry [100, 101], and the pH of the 
medium [95]. Therefore, increasing the porosity and surface area of PSi accelerates its 
degradation rate by increasing the surface contact for hydrolysis [99]. Moreover, the surface 
chemistry affects in two ways to the degradation rate of PSi. First, it determines the 
hydrophilicity, and thus, the wettability of the surface of the pores; and second, it is related 
to the chemical resistance to hydrolysis [95]. By modifying the hydrogen termination of 
freshly etched PSi to oxidized, hydrosilylated, or hydrocarbonized surfaces, the stability and 
biodegradability of PSi can be tuned, rendering less reactive species towards oxidation and 
hydrolysis [102, 103]. Lastly, an increase in the pH value of the medium accelerates the 
degradation rate of PSi due to the presence of OH?mediating the hydrolysis of the Si-H and 
Si-Si bonds [95, 99]. Thus, all these parameters should be take into consideration when 
designing PSi for biomedical application, in order to obtain the most adequate degradation 
rate according to the particular potential application.
92.1.2.3 Biomedical applications: drug delivery
From the first reference in the literature to the potential applicability of PSi in vivo [62],
numerous in vitro and in vivo studies have boosted the development of this material for 
biomedical applications, such as implants [104], biosensors [105], in vivo imaging agents
[86, 88, 106], and drug carriers [83, 107, 108]. In particular, the beneficial biocompatibility 
and biodegradability of PSi, along with the vast surface area-to-volume ratio and pore 
volume, makes them ideal candidates as drug delivery vehicles [81, 85, 101, 109].
In this regard, the loading and adsorption of drugs into the pores of PSi and their release 
is ruled by many factors that can be tuned in order to successfully load and release different 
kinds of cargos. Among these factors are the surface area and the pore volume, which 
determine the amount of drug that can potentially be loaded; the degradation rate of PSi
itself (Section 2.1.2.2) [110]; and the surface chemistry, which determines the
physicochemical properties of the surface of the pores and the interactions between the pore 
wall, the solvent used to load the drug, and the drug [111, 112]. Other parameters that have 
an impact on the loading of drugs into the pores of PSi are related to the solvent used and 
the properties of the drug. The wettability of the pores is dependent, in addition to the surface 
properties of the pores, on the surface tension and the viscosity of the drug solution. Low 
viscosity and surface tension allow better filtration of the solvent into the pores and, hence
improving the drug loading. Furthermore, the physicochemical properties of the drugs and 
the concentration also play a role in drug loading into PSi. However, although these
parameters are understood, predicting the loading degree of a certain drug molecule in the
pores of PSi is still rather challenging [111].
Drug loading within PSi can be achieved by immersion, impregnation, or covalent 
attachment, among others. The most commonly used, the immersion method [26, 111],
although unpredictable, is reproducible as long as the properties of PSi remain invariable
[111]. This method consists of the immersion of PSi in a drug solution for a certain period 
of time, usually in the range of hours, to allow the solvent to diffuse into the pores carrying 
the drug, which is adsorbed on the pore walls driven by geometrical and chemical 
interactions. The solvent is then removed and PSi can be carefully rinsed with an appropriate 
solvent to remove the drug bound to the external surface. Loading can be performed at room 
temperature, which is very convenient when handling thermosensitive molecules, such as 
peptides. However, relatively high concentration of drug solutions are required for the 
loading, thus rendering the immersion method not optimal for the loading of valuable drugs
[26, 111]. Therefore, other methods to incorporate drugs into PSi, such as impregnation or 
covalent grafting, might be advisable when handling these drugs [111]. In the impregnation 
method, the drug solution is mixed with the mesoporous material and the solvent is dried,
forcing the diffusion of drug into the pores [111, 113, 114]. In this way, the drugs may be 
efficiently loaded, although the adsorption of the drug on the surface is difficult to control
[64].
Drug molecules loaded in the mesopores of PSi are stabilized by the confined pore space
that limits their arrangement in crystal lattices. Thus, drugs remain in their amorphous state 
or form nanocrystals, providing to these molecules with different physicochemical 
properties than the ones found for the bulk drug. This has been translated into improved
dissolution of poorly water-soluble molecules and sustained dissolution of water-insoluble 
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molecules loaded into surface stabilized TOPSi and TCPSi [26]. In this respect, the 
dissolution rate of a number of poorly water-soluble drugs has been enhanced, including 
furosemide [26, 115], griseofluvin [26, 116], ibuprofen [117, 118], indomethacin [119],
itraconazole [120], sorafenib [121], ethionamide [122], celecoxib [83], or
saliphenylhalamide [123].
Along with the properties of the drugs, the pore size, surface chemistry, and loading 
degree, have also demonstrated to affect the kinetics of the delivery of drugs. In one study, 
PSi MPs with varying pore sizes (17?58 nm) were loaded with different amounts of the 
poorly water-soluble drug celecoxib (5?36%) in order to study how these parameters 
affected to the physical form of the drug, as well as to its in vitro and in vivo performance
[83]. It was reported that while celecoxib loaded in the PSi MPs with smaller pore size was 
found in a non-crystalline form, the larger pore size and loading degree favored the 
crystallization of celecoxib in the pores with formation of bigger drug crystals with 
increasing pore size. However, pore size, and thus, celecoxib crystal formation did not have 
a major effect on the in vitro release of celecoxib, since the crystal growth inside the pores
of PSi was limited by the pore dimensions, thus yielding nanocrystals with high surface 
area, which aided drug dissolution. Alternatively, the drug loading degree showed to 
influence the release rate of the drug. The lower drug loading degrees were found to enhance 
the release rate in vitro compared to higher drug loading degrees, by preventing the local
accumulation of large amounts of drugs at the pore opening during the drug release, which 
might recrystallize on the external surface of the particles forming bigger drug crystals with
slower dissolution rate profiles, and thus, blocking the pores. Accordingly, low drug loading 
degree was also found to improve the bioavailability of celecoxib in rats after oral 
administration [83].
Relative to the surface chemistry, a study comparing the effect of PSi with six different 
surface chemistries on the loading and release of ibuprofen was carried out [117]. The 
studied were as-anodized PSi particles, TCPSi, TOPSi, annealed TCPSi, annealed TOPSi, 
and THCPSi. The release profiles showed that the surface chemistry affected the dissolution 
enhancing properties of these particles. In particular, TCPSi MPs presented the highest 
capacity to improve drug dissolution. Likewise, in another study, acyclovir release profiles
from UnTHCPSi, TOPSi, and native PSi were assessed [124]. UnTHCPSi particles with 
more stable Si‒C chemistry showed a steadier drug release than TOPSi and native PSi, 
showing that acyclovir release could be modified by changing the surface chemistry of PSi.
Another approach for the loading of drugs into PSi, which further allows a better control 
of the drug delivery, is the covalent grafting of drug molecules onto its surface [125, 126].
The release of drugs from these PSi‒drug conjugates is mediated by the cleavage of the 
covalent bond between the PSi and the drug, or by the degradation of the Si structure. In 
this respect, drug release can be controlled by tuning both the liability of the chemical bonds 
or the degradation rate of PSi [111]. However, this methodology admits a reduced drug 
loading degree compared to the physical adsorption, since it is limited by the number of 
moieties available for the conjugation of the drug [111]. Moreover, the activity of the 
released drug has to be confirmed. Following this methodology, methotrexate was 
conjugated to PSi NPs through an ester bond rendering PSi-methotrexate conjugates capable 
of sustaining the release of the drug for up to 96 h [127]. In addition, the combination of the 
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drug with PSi enabled improved cellular uptake of methotrexate and in vitro
antiproliferative effect in a cell culture.
2.1.2.4 Progress in PSi-based DDS
In addition to the promising features that PSi offers, further modifications can be done to 
this material to enrich its application in the drug delivery field. The most relevant 
modifications on PSi have been done towards the controlled and targeted drug delivery
[128], along with magnetic or in vivo imaging properties [88, 129].
A major drawback limiting the application of PSi particles for the delivery of drugs is 
the uncontrolled release of the loaded cargo. Upon administration, the pores of PSi are 
readily accessible by the body fluids that can rapidly displace the payload resulting in 
uncontrolled and off-target premature drug release. This issue has been addressed by 
capping the pores of PSi by different methods, such as oxidation-induced trapping [72],
grafting pore gating systems [107, 130], or by physically capping the pores or encapsulating 
the PSi particles within other carriers [107, 108].
Oxidation-induced trapping of drug molecules into the pores of PSi uses the contraction 
of the mesopores occurring during oxidation of the Si matrix to increase the retention of 
drugs [72]. In this way, two model compounds, cobinamide and rhodamine B, were loaded 
into a PSi film, together with sodium nitrite, which enabled the oxidation of Si.
Subsequently, the drug-loaded films were fractured by ultrasonication into MPs, and the
release rates of the compounds were found to be prolonged by 20-fold compared to PSi 
samples loaded with the compounds after oxidation.
Especially interesting are the DDS capable of responding to external stimuli as the
trigger for drug release in order to achieve spatiotemporal control of this process (Section 
2.1.3.2). This approach has also been used in combination with PSi particles. For example,
a smart DDS combining PSi NPs with a pH-triggered nanovalve system was recently 
reported [107]. The nanocomposite was prepared by grafting a pH-responsive cationic 
polymer, poly(beta-amino ester), to PSi NPs loaded with DOX. In addition, due to the 
hydrophobic nature of the grafted polymer, the system was further stabilized with F127, a 
triblock copolymer containing poly(ethylene) oxide and poly(propylene glycol). First, F127 
was used to prepare micelles loaded with paclitaxel that were, subsequently, assembled on 
the surface of the polymer grafted PSi NPs. The resulting nanocomposite achieved
sequential combination therapy through the steady release of paclitaxel along with a pH-
triggered release of DOX upon acidification of the release medium (pH 5) for the site-
specific release of DOX. The nanocomposite also demonstrated enhanced colloidal stability 
and good cytocompatibility.
Regarding the physical pore capping or encapsulation of PSi particles to control the 
delivery of drugs, a number of polymers and lipids have been used, such as poly lactide-co-
glycolide [131, 132], glycerol monostearate, and phosphatidylcholine [28]; or stimuli 
responsive compounds, such as hydroxypropylmethylcellulose [90, 128], acetalated dextran
[133], or poly(N-isopropylacrylamide-co-diethylene glycol divinyl ether) [131]. For 
example, PSi has been functionalized with a polymer film to achieve sustained and
temperature-dependent delivery of drugs [108]. Therefore, PSi loaded with the anticancer 
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drug camptothecin was coated with the temperature-responsive poly(N-
isopropylacrylamide-co-diethylene glycol divinyl ether) that underwent physical transitions
when heated beyond the lower critical solution temperature of 32 °C. In this fashion, the 
composite achieved to quench the burst release of the drug from bare PSi, as well as to 
sustain the release of drug along the time at 25 and 37 ºC, when this effect was more 
pronounced at 25 ºC.
PSi has also been used as a vehicle for other DDS. For example, APTS-modified PSi
MPs (1.6 ± 0.1 μm) with a pore size of 30 nm were loaded with liposome encapsulated 
paclitaxel for the targeted delivery of the payload to endothelial cells and bone marrow 
tissue [134] mediated by APTS binding to E-selectin receptors. Similarly, hemispherical 
PSi particles have been loaded with DDS to create NP-in-MP multistage vectors [135, 136].
In this respect, the size, shape, and surface chemical properties of the PSi particles were
analyzed in order to tune their i.v. tissue distribution, revealing that the hemispherical PSi 
MPs were more likely to accumulate in the tumor endothelial and perivascular depots where 
the therapeutic payload was then released. This accumulation was achieved by the optimal 
hydrodynamic forces and interfacial interaction of these particles with the tumor 
vasculature, thus representing the best configuration as a vector for delivery of 
nanotherapeutics [137, 138].
PSi particles have also been targeted to certain organs or diseases, including bone 
marrow, mediated by APTS binding to E-selectin receptors [134]; subcutaneous MDGI-
expressing tumors, mediated by a homing-peptide [139]; neuroblastoma, glioblastoma and 
B lymphoma cells, mediated by antibodies [140]; and prostate cancer, mediated by the 
homing-peptides RGD and iRGD [141]. However, efficient targeting of i.v. administered 
PSi particles is still compromised by the rapid clearance from the blood stream, therefore it 
is highly advisable to combine such targeted systems with other methods to prolong their 
blood circulation time. For example, dual-PEGylated TOPSi NPs presenting a high-density 
of Poly(ethylene) glycol (PEG) coating with both brush-like and mushroom-like 
conformations have been developed [142], demonstrating improved colloidal stability in 
salt solutions and reduction in both protein adsorption and macrophage uptake, features that 
could potentially be beneficial for the i.v. administration of PSi.
Other interesting properties in the field of drug delivery have been implemented in PSi, 
like magnetic properties for remote-guided targeted drug delivery (Figure 1). In this respect, 
PSi MPs were simultaneously loaded with superparamagnetic iron oxide NPs (SPIONs) and 
the anticancer drug DOX [129]. These particles were incubated with a cell culture and 
magnetically guided to promote the concentration of the particles in the vicinity of the 
magnetic field resulting in a high concentration of drug being released in that region of the 
Petri dish, which in turn resulted in localized cell death as confirmed by fluorescence cellular 
viability assay.
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Figure 1 In vitro remote-guided targeted drug delivery. (a?d) Phase contrast microscope images 
of HeLa cells corresponding to different regions of the petri dish after 24 h incubation 
with DOX-loaded magnetic PSi MPs under the influence of a magnetic field placed on 
one side of the Petri dish (refer to figure i). (e?f) Fluorescence microscope images of 
HeLa cells stained with calcein acetomethoxy corresponding to the same positions as
a?d images, respectively. (i) Representation of the relative position of the magnet and 
each image (a?d) in the Petri dish. (j, k) Phase contrast and fluorescence microscope 
images of a negative control dish of HeLa cells. Scale bar for all images is 100 μm.
Reprinted with permission from ref. [129].
2.1.3 Lipid and polymer-based DDS
The first DDS to reach the market was PEGylated liposomal DOX in 1995, approved by the 
Food and Drug Administration [143], and, to date, lipid-based DDS have still been the most 
successful candidates in the race for clinical approval [1]. One of the reasons for the success 
of lipids in the formulation of DDS is their biocompatibility and biodegradability [17, 18].
However, biodegradable polymers are considered a good alternative to lipids because of
their improved in vivo stability and tunable degradability [19].
In the past few years, lipid based particulate systems have been increasingly reported,
such as nanostructured lipid carriers [144], emulsions [145], lipid–drug conjugates, lipid
nanoparticulates [146], and polymer-lipid hybrid NPs [147]; but the major focus has been 
on liposomes and solid lipid NPs [148]. Most of these lipid-based DDS have been used to 
solubilize poorly water-soluble molecules to improve their bioavailability in the body [149],
and one example of this are the liposomes, which have demonstrated excellent loading 
capacity and retention of hydrophilic drugs within their aqueous core through remote 
loading, guided by chemical gradients [150-152]. In addition, hydrophobic molecules have 
been successfully loaded and solubilized within the lipid bilayer of the liposomes [153].
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Meanwhile, polymers hold the advantage of versatility, existing a number of natural and 
synthetic polymers with varying backbones to alter the release rate of drugs, and presenting 
the capacity to attach ligands for active targeting purposes. Among them, biodegradable 
polymers are desirable [19]. Polymeric NPs or self-assembled micelles from amphiphilic 
block copolymers are of particular interest in the drug delivery field, together with polymer-
based DDS and polymer-drug conjugates, which are becoming widely utilized standard 
method to improve the circulation and bioavailability of biomacromolecules, such as 
antibodies [19].
In the following sections, the fabrication of different lipid- and polymer-based DDS
related to this work will be discussed, as well as some of their advanced drug delivery 
applications.
2.1.3.1 Fabrication of lipid- and polymer-based DDS
Numerous approaches have been applied for the production of lipid- and polymer-based 
particles for drug delivery applications, often making use of amphiphile lipidic and 
polymeric molecules, which are capable of self-assembling in water to produce 
supramolecular structures. The most commonly used methods to drive and tune the self-
assembly of these molecules are [32, 154-156]:
? solvent-switch method, in which the amphiphiles are dissolved in a solvent that
is gradually switched for another solvent where one of the blocks of the 
amphiphile is not soluble;
? film rehydration method, which is based on the dissolution of the amphiphiles 
in an organic solvent, further removed to obtain a film that is then rehydrated 
with aqueous-based solutions;
? direct dissolution method, where the bulk lipid or polymer is directly dispersed 
in the aqueous solutions;
? microfluidics technology, which consists on the formation of particles from a 
single, double, or more, emulsion template produced inside microchannels;
? and nanoprecipitation method, in which a solute-containing solvent is mixed 
with a non-solvent, becoming the solute highly supersaturated and 
spontaneously nucleating.
In particular, the microfluidics technology and the nanoprecipitation method were the 
approaches used in this thesis for the production of lipid and polymer-based MPs and NPs,
and will be described in detail in the following sections.
Microfluidics technology
The microfluidics technology consists of the manipulation of small volumes of fluids in the 
order of 10-9 to 10-18 L, making use of microchannels [157]. It has been exploited for a 
variety of applications, such as high throughput separation and detection of compounds
[158], chemical synthesis [159], fluid optics [160], manipulation of cells [161], biomimetics
[162], microbiotic systems [161], and manipulation of fluids [163]. Microfluidics offers
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possibilities that are non-existent in the bigger scale, like the capacity to use tiny quantities 
of samples and reagents, detect and separate compounds with high resolution and
sensitivity, and exploit the laminar flow occurring at the microchannels; while reducing the 
cost time and footprint of the process [164].
Particularly relevant to this work is the application of microfluidics for the manipulation 
of multi-phase flows in order to produce lipidic and polymeric-based particles. In this field
there are a number of approaches used, among which are: (i) single emulsion-templation
[165, 166]; (ii) double emulsion-templation [163], (iii) and rapid mixing [33]. The first two 
techniques render single or double emulsion drops in the micrometric range, while the last 
is based on the mixing pattern of fluids, allowing the production of particles in the
nanometric range. By controlling the flow rates of the fluids pumped inside the capillaries,
the viscosity and interfacial tension of the fluids, and the type and concentration of the 
polymers or lipids used to stabilize the droplets or form the NPs, the size of the droplets and 
NPs can be finely tuned. Moreover, highly monodisperse droplets and NPs, with high 
encapsulation efficiency are obtained [33, 167-169].
Two of the most representative devices used in microfluidics for the production of 
particles typically consist of microchannels etched primarily on a Si rubber of 
poly(dimethylsiloxane) (PDMS) using soft lithography [157], and chemically attached to a 
glass slide; or a circular capillary or a series of them inserted concentrically into another 
capillary and co-axially aligned and glued to a glass slide [170]. A difference between these
two techniques in terms of the resulting flows achieved is that the glass capillary chips allow 
the production of truly three-dimensional flows [32] compared to the PDMS chips (Figure
2). Adittionally, the chemical compatibility of PDMS devices is very limited, hindering the 
utilization of PDMS device with strong solvents. In contrast, glass capillary devices are very 
robust and compatible with a wide variety of solvents [171]. However, the etching of 
microchannels in PDMS can be performed in parallel, rendering a high production 
efficiency, compared to glass capillary devices, which have to be assembled individually by 
hand.
Figure 2 Schematic illustration of the geometry of droplet formations in (a) a PDMS microfluidic 
device. D: dispersed fluid, CF: continuous fluid for emulsification, CF2: continuous
fluid for encapsulation. (b) Glass capillary flow- focusing microfluidic device. It can 
be observed how with the glass capillary devices truly 3D flows can be achieved 
compared to the PDMS device. Reprinted with permission from refs. [32, 172] and
from ref. [173]. Copyright 2014 American Chemical Society.
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Single and double emulsion microfluidic fabrication of microcarriers
Single and double-emulsion microfluidic templated production of MPs is based on the 
formation of two or three phases emulsion droplets, usually oil-in-water or water-in-oil-in-
water droplets, stabilized by amphiphilic molecules, which after the evaporation of the oil 
phase render the MPs. The principle of droplet formation in the micrometric channels lays 
on the hydrodynamic instability of the inner flow [174]. Droplets might be formed by two 
different regimes called dripping or jetting. In the first one, the droplets form when the 
surface tension of the incipient droplet leaving the inner capillary is overcome by the viscous 
drag of the outer fluid. In the second regime, droplets are formed from a stream of fluid that 
eventually breaks down, based on the Rayleigh-Plateau instability [32]. When the inner fluid 
jet is slightly disturbed a thinner region is formed, leading to the curvature of the interface
between the two fluids and the increase in the internal pressure of the water, as explained 
by the Laplace pressure, pushing the fluid within the jet to the sides and forcing the 
narrowing of the thinner part of the jet until it breaks up into droplets [32].
The glass capillary microfluidics devices offer the possibility of building a variety of 
geometries (Figure 3) for the production of single and double emulsion droplets. Single-
emulsion microfluidics devices consist of an inner circular capillary tapered to a certain 
diameter and inserted into another glass capillary with which two fluid geometries can be
achieved: co-flow and flow-focusing. In the co-flow geometry (Figure 3a) the inner phase 
is pumped into the inner capillary and the outer phase into the outer capillary, through the 
space between the inner and the outer capillaries, and in the same direction as the inner
phase [175]. In the flow-focusing geometry (Figure 3b) the inner and outer phases are
pumped into the outer capillary in opposite directions. When the fluids come into contact, 
they form an interphase and the outer fluid focuses the inner phase into the collection inner 
capillary were the droplets are formed [175].
Double emulsion microfluidics devices combine both the geometries, although different 
configuration of the capillaries can be used to achieve similar results [163, 176]. A design 
for double emulsion production is given in Figure 3c, consisting of two tapered capillaries,
injection and collection, inserted at each side of an outer capillary. The inner and middle
phases co-flow pumped into the inner injection and outer capillaries, respectively; while the 
outer phase, flowing in the opposite direction, focuses both inner and middle phases into the 
collection capillary, forming the double emulsion droplets [175].
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Figure 3 Schematic representation of glass capillary microfluidics devices. (a) Co-flow single-
emulsion production approach. (b) Flow-focusing single-emulsion production 
approach. (c) Double-emulsion production approach combining co-flow and flow-
focusing. Reprinted with permission from ref. [175].
Fabrication of nanocarriers based on nanoprecipitation
The nanoprecipitation technique was first patented by Fessi et al. [177] and described as “a
process for the preparation of dispersible colloidal systems of a substance in the form of 
spherical particles of the matrix type and of a size less than 500 nm”. Following, in the same 
document, the process was described. For this, two liquid phases are needed: the first is a 
solution of the substance in a solvent or a mixture of solvents, and the second is a non-
solvent or a mixture of non-solvents for the substance; being both miscible and containing 
or not surfactants. Either of the liquid phases may be added to the other with moderate 
stirring to produce a colloidal suspension of NPs almost instantaneously, and optionally the 
solvent may be removed from the final NP suspension. According to this patent, practically 
any substance sufficiently soluble in a given solvent can be used to produce NPs in this 
fashion. Based on this phenomenon, a large number of drug carriers have been produced,
from classical polymers, such as poly(lactide) [178, 179], poly(caprolactone) [180], and 
poly(lactic-co-glycolic acid) (PLGA) [181]; to amphiphilic copolymers forming a core-shell 
structure [182, 183].
The formation of NPs by this method has been suggested to be triggered by the so-called
“Ouzo effect” by Vitale and Katz [184, 185]. Based on a ternary phase diagram of the 
concentration of solute, solvent, and non-solvent, the Ouzo region represents the 
composition of these three components where only NPs are obtained (Figure 4a) [186].
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This effect occurs because, upon mixing with a non-solvent, the solute becomes greatly 
supersaturated in certain regions where the nuclei of the solute are formed spontaneously,
depleting the solute close to them, and limiting further nucleation in the close vicinity. The 
nucleation ends when there are not supersaturated regions remaining [184].
Nucleation has been explained by the classical nucleation theory. On the ternary phase 
diagram, the Ouzo region is a metastable region delimited by the spinodal and binodal 
curves, representing the limit of thermodynamic stability of the solution and the miscibility 
limit upon solvent composition, respectively (Figure 4a) [187]. When a critical 
supersaturation of the solute is reached (the supersaturation is defined as the ratio of the 
solute concentration to the equilibrium solubility) in the metastable Ouzo region, nuclei 
form spontaneously from small local fluctuations in the concentration of the solute [186].
Particles with a radius smaller than the critical radius, r*, corresponding to the maximum of 
free energy, vanish, whereas above r*, particles are stable and can grow further [186].
Growth may happen through two mechanisms, both resulting in monopopulated NPs
(Figure 4b and 4c) [188]. The first of them is limited by the diffusion coefficient of the 
solute molecules and by the supersaturation, when the growing nuclei stick solute molecules 
around them until the solute equilibrium concentration is reached (Figure 4b); the second
mechanism takes place mostly when the nuclei concentration is very high, since the 
probability of collision is proportional to the square of the number of particles. Therefore, 
the nuclei collide and rearrange forming dense structures (Figure 4c) [186, 188].
Figure 4 (a) Three-component phase diagram at constant temperature and pressure. The weight 
fraction of a solute on the solvent is represented on the abscissa, and the weight fraction 
of the solvent on the ordinate. The weight fraction of the non-solvent is found by 
difference. (b) Schematic representing nucleation growth limited by diffusion of solutes 
and supersaturation. (c) Schematic representing nucleation growth based on cluster-
cluster aggregation. Reprinted with permission from ref. [184, 186].
The further growth of these NPs upon diffusion of dissolved solute my take place on a 
longer time scale driven by the Ostwald ripening, which defines that the total energy of the 
two-phase system can be decreased via an increase in the size scale of the second phase, and 
thus, a decrease in total interfacial area [189]. This can be prevented by the addition of 
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stabilizers. However, surfactants are often not necessary if the NPs contain hydrophilic 
moieties or non-neutral charge that promote the NPs’ stability [190].
In addition to the initial concentration of polymer in the solvent, and the solvent/non-
solvent ratio, there are other relevant parameters to control the size of the NPs produced by 
the “Ouzo effect”, such as the diffusion coefficient of the solvent and non-solvent, the 
viscosity, and the speed of the mixing process; factors that determine the mixing time of 
both liquids, since faster mixing has been reported to lead to smaller NP size [33, 191, 192].
Nanoprecipitation generates kinetically frozen NPs, meaning that the NPs grow until the 
energy barrier for the insertion of a chain becomes high enough, and this energy is 
dependent on the magnitude of the solvent quality change, being lower when the solvents 
diffusion is not complete and allowing the growth of the NPs. Thus, for a mixing time 
greater than the aggregation time (τmix > τagg), the size of the NPs is dictated by the mixing 
time and the initial polymer concentration, while for τmix < τagg, the NPs size is expected to 
be independent on the polymer concentration [192, 193].
For the above mentioned reason, different designs have been explored to ensure a fast 
and reproducible mixing pattern of the solvents [193-195]. One of the mixing techniques
exploited and also applied in this thesis is based on microfluidics [33, 196]. The mixing 
process in microfluidics channels can be laminar or turbulent. Laminar mixing is achieved 
through hydrodynamic flow-focusing, in which an inner stream is narrowed and focused 
enabling the rapid diffusion of solvent and non-solvent inside and outside the stream, and 
thus, the nanoprecipitation of the solute (Figure 5a) [191]. In this respect, a study reported
that the size and polydispersity, as well as the drug loading and release of NPs consisting of 
PLGA‒PEG produced in this fashion, could be controlled by varying the flow rates, the 
polymer composition, and the polymer concentration [191]. Another study systematically 
screened the influence of the Reynolds number (Re) on the resulting NPs produced by 
microvortices-based mixing (Figure 5b) [33, 34]. The Re defines the flow pattern under 
different fluid flow situations and can be represented by the following Equation 1:
?? ? ?????? ?
??
?? (Eq. 1)
where ρ represents the viscosity of the fluid, U the average velocity of the fluids, L0 the
diameter of the pipe, μ the density of the fluid, Q the flow rate, and E the channel inner 
diameter.
For a given microfluidic setup, by increasing the viscosity of the liquids or the flow rate, 
or by decreasing the density of the fluids, a higher Re is achieved. Transitioning from low 
to high Re dictates changes in the mixing patterns of the fluids inside a microfluidic device 
from laminar flow to microvortices, to unsteady jetting [33]. Accordingly, NPs prepared 
from PLGA, hydrophobic chitosan, and acetalated dextran showed smaller sizes at higher 
Re [33, 34]. Moreover, NP size has been shown to be even more sensitive to Re than to the 
solute composition, which is indicative of the important of the mixing speed in the formation 
of NPs [34].
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Figure 5 Schematic representation of the nanoprecipitation process in a microfluidic device by
(a) hydrodynamic flow focusing and (b) microvortices. Reprinted with permission from 
ref. [34, 191].
2.1.3.2 Progress in lipid- and polymer-based DDS
To continue with the progress achieved in the last decades regarding novel approaches to 
control the delivery of drugs, current research focuses on the targeting of the DDS to the 
absorption or disease site where drug release is then triggered. Often, the carriers used for 
this tasks are lipid- or polymer-based DDS. Other tumor-specific strategies using DDS will 
be discussed in Section 2.3.2.
Active targeting of the lipid and polymer DDS is based on the functionalization of their 
surfaces to promote the affinity towards specific receptors/markers expressed by certain 
tissues/cells or under certain physiological conditions. Functional ligands decorating the
DDS might be peptides, antibodies, sugars, lectins, etc. [197]. However, active targeting of 
DDS generally does not account for conformational changes or chemical instability that the 
ligands may suffer, or for the colloidal aggregation of particles, which hinders the exposure 
of the ligand [198]. Moreover, drug targeting in this fashion is a stochastic process that relies 
on the primary random contact of the particle with the target site to trigger the targeting 
mechanism [199].
In addition, other approaches are used for the targeted drug delivery of DDS. This is the 
case of DDS targeted by external stimuli, such as magnetic field, or ultrasound, which allow 
real-time targeting even to deep-seated tissues, remote triggering of drug release, and,
additionally, simultaneous imaging and therapy [197]. For example, local heating of tumors 
by microwave or ultrasound superficial hyperthermia, used to trigger the release of DOX
from liposomes by transition temperature of the liposomes, is already in clinical trials [200].
In addition, focused ultrasound has been found to reversibly disrupt and create gaps in the 
epithelial cell layers of the blood brain barrier (BBB) and blood-tumor barrier, allowing 
drugs and drug nanocarriers to escape the blood vessels into the target tissues [201].
Hyperthermia treatment of tumors can also be promoted by irradiating metallic NPs that
absorb light and convert it into heat. For example, heat sensitive poly(N-
isopropylacrylamide) and a poly(N-isopropylacrylamide)-co-poly(acrylamide), have been 
designed to present low critical solution temperatures of 32 and 39 ºC, and, when coating
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hollow porous gold nanostructures and upon near-infra red laser irradiation, the polymers 
shrink uncovering the pores and allowing drug efflux [202].
Moreover, other complex systems have been reported for the targeting of DDS. For
example, communication between gold nanorods, magnetofluorescent iron oxide 
nanoworms, and DOX-loaded liposomes in vivo has been achieved, promoting tumor 
targeting of the liposomes through the activation of the machinery of an endogenous 
multistep biological cascade [203]. Tumor-targeted gold nanorods converted external 
electromagnetic energy into heat to locally disrupt tumor vessels, resulting in the activation 
of the coagulation cascade. In addition, coagulation was activated by circulating peptides 
that targeted coagulation enzymes activity by acting as a substrate for the coagulation 
transglutaminase factor XIII. Circulating iron oxide nanoworms and DOX-loaded 
liposomes coated with peptides capable of recognizing fibrin were therefore recruited by 
their interaction with the fibrin produced in the coagulation cascade at the tumor.
Another challenge faced by lipid- and polymer-based DDS is the insufficient drug 
loading and off-target drug release. Different approaches have been used to overcome this 
issues, such as the fabrication of crosslinked polymeric NPs to avoid degradation and 
premature drug release in the body fluids [204], or particles formed from lipid or polymer 
drug conjugates. For example, the natural lipid squalene, capable of forming NPs in its 
folded conformation has been conjugated to drugs, achieving 5 times more drug loading
than liposomes [205].
Other strategies aim to endow lipid- and polymer-based DDS with the capacity to 
overcome biological barriers, such as the BBB. For example, NPs with certain properties 
are capable of interacting with the BBB-forming cells at a molecular level achieving the 
transport of drugs across the cell barrier [206]. In this regard, poly(butyl)cyanoacrylate NPs
coated with Tween-80 were capable of binding apolipoprotein E, thus appearing as a low 
density lipoprotein for the endocytic cells of the BBB [207]. This allowed the entry of drug-
loaded NPs into the cell from where the drug was effluxed into the brain parenchyma. 
In some cases, even the intracellular targeting of DDS is required, when the therapeutic 
action of the drug is on a target within the cell, i.e., intracellular peptides, enzymes, nucleic 
acids (DNA/RNA) [197]. Intracellular targeting involves the access of the DDS through the 
endocytic pathway into an endosome which further becomes a lysosome. Lysosomes are 
acidic and contain hydrolytic enzymes that degrade the material inside it; therefore, it is
crucial that the active molecules escape to the cytosol intact. DDS used for intracellular 
targeting are usually stimulus responsive carriers that initiate their release into the cytoplasm 
via endosome or lysosome-disruption. Generally, cationic lipidic or polymers are used due 
to their proton-sponge properties. These molecules protonate upon acidification of the 
endosomal compartment creating an osmotic flow from the cytoplasm to the endosomes or 
lysosomes, increasing the pressure on the organelle that leads to its disruption [208]. Some 
of the lipids or polymers with proton sponge capabilities are molecules containing primary, 
secondary, tertiary or quaternary amines, or other positively charged groups. In this respect, 
lipids or polymers containing histidine or imidazole rings [209], polyethylenimine, 
polyamidoamine, polylysin, etc., have been used for intracellular drug delivery [208].
22
2.2 Nanomedicines for tumor therapy
2.2.1 Biological barriers for nanomedicines in tumor therapy
To efficiently reach the tumor site, newly developed nanomedicines have to face multiple 
barriers. Among them, there are the body’s natural barriers and the tumor pathological 
barriers (Figure 6). The first hindrance that the nanomedicines face after i.v. injection is the 
rapid clearance from the blood circulation by direct renal filtration or by the MPS [12, 13].
The filtration cut-off of the kidney has been reported to be of 5.5 nm, demonstrated by the 
fact that particles smaller than this size were directly excreted with the urine [12]. In 
addition, non-stealth NPs are rapidly opsonized by the blood serum proteins, which
promotes their phagocytosis by the MPS [210] via attachment of the phagocyte to the NP
through surface bound opsonins [211]. Non-biodegradable NPs that fail to be completely 
degraded by the phagocyte machinery will further accumulate in the associated MPS organs, 
liver and spleen [13]. Therefore, ideally, NPs should have stealth properties in order to 
prolong their circulation time and to increase their chances to extravasate at the tumor site
[16, 212].
Figure 6 Physiological characteristics of the tumor tissue and vasculature relevant for the 
development of DDS for tumor therapy. Reprinted from ref. [14]
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There are characteristic properties of the solid tumors that in principle help to the 
progression of the disease, but that can also serve to engineer nanomedicines that, taking
advantage of these properties, specifically reach the tumor site [213]. These are the structure 
and architecture of the tumors, the cell surface, and the molecular targets. Cancerous cells 
are characterized by uncontrolled proliferation due to their replicative immortality, 
resistance to cell death, sustained proliferative signals, and metastatic capacity. Moreover, 
cancer cells are capable of evading growth suppression signals and immune system 
recognition [214]. Because of the rapid proliferation of cancer cells, the vessel density 
supplying oxygen to the tumor mass might drop generating hypoxic conditions [215]. In 
turn, cancer cells respond by reducing oxygen consumption and, if continued, adapting their 
metabolism by increasing glycolysis to maintain ATP production [216]. In addition, 
hypoxic and necrotic conditions induce the production of vascular endothelial growth 
factors, which promotes angiogenesis [214, 215]. In general, the balance of pro- and anti-
angiogenic signals in tumors is not balanced, leading to a constant endothelial cell growth
[215]. This situation causes the tumor vessels to fail forming defined structural features of 
arterioles, venules, or capillaries, and instead they grow caothically [215, 217]. Moreover, 
perivascular cells, encountered in close contact with endothelial cells in normal tissues, and 
in charge of controlling their proliferation, are found loose and in lower amount in tumor 
angiogenic blood vessels [218, 219]. As a result, some tumor vessels present a defective 
endothelial monolayer with disorganized, and loosely connected, branched, and overlapping 
endothelial cells [213]. In a study by Hashizume et al. [213] it was shown by scanning
electron microscopy (SEM) the defective endothelial monolayer of vessels irrigating mouse 
mammary carcinomas, which are known to be leaky. They found out that 14% of the luminal 
vessel’s surface presented poorly connected and overlapping endothelial cells with 
intercellular openings with a mean diameter of 1.7 μm, and also some transcellular openings 
of 0.6 μm mean diameter. Besides the widely explored tumoral leaky vasculature, a novel 
discovery has been reported [220]. Using intravital confocal laser scanning microscopy, 
stochastic bursts were observed in the tumor vasculature that led to dynamic vents through 
which a brief and vigorous outward flow of fluid and NPs extravasated to the tumor 
interstitial space. In this respect, long circulating NPs could better take advantage of this 
phenomenon, which also would allow the extravasation of large particles. 
In addition to the enhanced tumor permeation, the interstitium of the tumor is 
characterized by deficient lymphatic drainage which promotes high interstitial pressure 
[221, 222]. In combination with the high permeability of the tumoral endothelial blood 
vessels, they render the so-called enhanced permeability and retention (EPR) effect, which 
is invariably found in all the solid tumors [51, 222]. This effect promotes the permanence 
of the therapeutic agents that extravasate the tumor blood vessels passively at the tumor 
interstitium [51]. However, the high intratumoral pressure may hinder the passive 
extravasation of therapeutic agents through the leaky vasculature, and may also tend to push 
the extravasated therapeutic agents to the margins of the tumor, resulting in their inefficient 
uptake [223]. In addition to the high interstitial pressure, poor lymphatic drainage, together 
with the propensity of tumors for glycolytic metabolism of glucose to lactate, render the 
tumor tissue slightly acidic [224, 225].
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2.2.2 Strategies for nanomedicines in tumor therapy
Understanding the biological barriers and tumor physiopathology has led to the rational 
design and development of multistage and multifunctional advanced nanomedicines for 
antitumoral applications attaining predictable properties in vivo (Figure 7).
To begin with, opsonization of particles defines whether or not these will be recognized 
by the MPS and cleared from the body. Accordingly, some parameters of the particles can 
be engineered to reduce or slow down opsonization, such as the size, surface charge, and 
surface hydrophobicity/hydrophilicity [226], although no definitive rules exist for 
completely blocking it [13]. Regarding the size of the DDS, NPs with diameters smaller 
than 5.5 nm are quickly excreted by the kidneys [12]; however, particles with diameters 
larger than 200?300 nm tend to accumulate to a greater extent into the MPS cells in the 
spleen and liver [14, 227]. In addition, hydrophilic non-ionic NPs have been found to 
prevent opsonization by steric stabilization, compared to hydrophobic NPs, which present 
enhanced adsorption of serum proteins on their surfaces [226, 228-230]. In terms of charge, 
neutral particles have demonstrated lower opsonization rates than positively or negatively
charged ones, likely due to the inhibition of the electrostatic interactions between proteins 
and particles [231, 232]; however, slightly negatively charged NPs in vivo have shown 
reduced liver accumulation and enhanced tumor accumulation compared to highly 
positively or negatively charged particles [233]. Therefore, to slow down opsonization 
hydrophilic polymers and non-ionic surfactants, such as polysaccharides, polyacrylamide, 
poly(vinyl alcohol), poly(N-vinyl-2-pyrrolidone), PEG, and PEG-containing copolymers,
are often adsorbed or grafted to the surface of NPs [13]. To date, PEG is the most widely 
used polymer to provide NPs with long circulation capacity [16, 49, 234, 235]. Although 
recent studies have suggested the immunogenicity of PEG after repeated injections followed 
by accelerated blood clearance, this issue still holds controversy, since administered doses, 
animal species tested, and the type of PEGylated NPs, among others, seem to play a key 
role on the blood clearance [236].
Many of the engineered NPs for tumor therapy rely solely on the EPR effect to 
extravasate to the tumor [47, 237-239], and have even reached the market, such as Doxil
[143], a PEG-based DOX liposomal formulation that shows a long circulation time in 
plasma, enhanced accumulation in murine tumors, and superior therapeutic activity over 
free DOX [49]. However, to further promote the extravasation and tumor penetration of 
therapeutic agents, these have been coupled to a variety of ligands that detect specific or 
overexpressed markers present on the endothelial cells’ surface of blood vessels irrigating 
the tumors [15, 240]. Although this approach has demonstrated to be more advantageous 
than simply targeting to tumor cells, which suffer from poor extravasation to the tumor 
tissue, more advance system have arose. In order to ensure the efficient extravasation and 
tumor penetration of nanosystems, tumor-penetrating peptides have recently been 
developed for targeting endothelial and tumor cells simultaneously, while being capable of 
penetrating into the tumor tissue [15]. Usually, the tumor penetrating peptides are developed 
by in vivo phage display [240], consisting of the screening of tumor molecular targets with 
phage random peptide libraries that specifically bind to them [240, 241]. Among others,
examples of tumor-penetrating peptides are given by LyP-1 [242] and iRGD [241], which 
demonstrated in vivo to mediate the extravasation and tumor tissue penetration of intact 
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particles coated with these peptides, therefore increasing the efficiency of the drugs 
transported. In particular, iRGD, a cyclic peptide (CRGDK/RGPD/EC), has shown great 
advantages for tumor accumulation of NPs in vivo [243, 244]. iRGD and iRGD-coated NPs
demonstrated to efficiently extravasate from the blood vessels, and accumulate at the tumor 
parenchyma, spreading around the tumor tissue in a metastatic tumor model [241]. This 
peptide specifically binds to αvβ3 and αvβ5 integrins upregulated in angiogenic endothelial 
cells and certain tumor cells [245]. Following, the sequence is proteolytically cleaved
exposing a C-terminal CRGDK motif that losses affinity for the integrins while gaining 
affinity for the receptor Neuropilin-1, which mediates tumor cells and tissue penetration
[241].
Figure 7 Pharmacokinetics of particles administered i.v. Tumor extravasation of particles is 
aided by the prolonged blood circulation time. Reprinted from ref. [14].
Despite all the advances, the battle for achieving tumor extravasation of NPs has gone 
further by tuning the geometry of the DDS in order to facilitate the adhesion to abnormal 
endothelium relying on the vascular blood flow patterns [198]. NPs follow intravascularly 
three steps: (1) lateral drift to the margins of the vessels, or margination; (2) firm adhesion 
to the endothelium; and (3) internalization [198]. Margination can be promoted by the 
26
rational design of particles to achieve their accumulation in the vicinity of the endothelial
cells, where laminar blood flow is observed. While classical spherical NPs rely on lateral 
external forces to marginate, such as gravitation [246], non-spherical particles tumble and 
roll, which can be used to control their margination dynamics without the need for external 
forces. Hence, larger discoidal, quasi-hemispherical and ellipsoidal particles are expected 
to adhere more efficiently to the endothelium of the vasculature than small spherical 
particles, due to a larger surface for adhesive interactions and greater margination propensity
[247, 248].
NP-based cancer theranostics has emerged as the next-generation tool for personalized 
medicine, consisting of the combination of therapeutic and diagnostic agents on a single 
entity [249-251]. Theranostic NPs can simultaneously be applied to non-invasive diagnosis 
and treatment monitoring of solid tumors in patients by in vivo imaging techniques, such as 
computed tomography, magnetic resonance imaging (MRI), positron emission tomography, 
single-photon emission computed tomography, and fluorescence imaging [252]. On one 
hand, since diagnosis or treatment monitoring is not necessary with every administered 
dose, two identical platforms can be used independently or combined for therapy and 
imaging; on the other if using safe and inexpensive imaging agents, a single NP could be 
utilized as well [253]. In this respect, DDS have been combined with a variety of imaging 
agents in order to obtain data on their accumulation at the target site. For example, 
radiolabeled PEGylated liposomes were monitored on the treatment of a patient with Kaposi 
sarcoma, observing accumulation and prolonged retention of the liposomes at the place of 
the lesions [254]. Paramagnetic and superparamagnetic NPs, such as gadolinium [255], iron 
oxide [256], or manganese [257], have also been used for theranostic applications of NPs,
because of their properties as MRI contrast agents. In addition, they have been utilized for 
magnetic guidance of DDS at the target sites by strong external magnetic fields and 
hyperthermia treatment of tumors [255, 258].
In addition to the satisfactory NP extravasation at the tumor site, efficient tumor 
treatment also relies on the stability of the NPs in the circulation and release of drug cargo 
inratumorally. In this way, it is possible to minimize undesirable off-target side effects of
chemotherapeutic agents, while maximizing the therapeutic efficacy of the drug. One of the 
classical triggers exploited for the spatial delivery of drugs from lipid and polymer DDS is
the pH. The characteristic pH values found at the tumors or metastases make a good example 
of it, and were already predicted as a potential trigger for drug release from pH-sensitive 
liposomes over 30 years ago [259]. Other designs make use of different stimuli as the trigger 
for drug delivery. These can be classified as intratumoral stimuli, such as interstitial or 
intracellular pH [260, 261], enzymatic actuation [262, 263], and reductive intracellular 
environment [264, 265]; and external stimuli, as described in Section 2.1.3.2, such as heat
[266, 267], radiation [268, 269], magnetism [270, 271], and ultrasound [272].
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3 Aims of the study
Despite the advances in the field of controlled drug delivery in the last decades, great efforts 
are still dedicated to the formulation of poorly water-soluble molecules into DDS in order 
to improve their pharmacological properties. PSi has long been demonstrated beneficial 
properties for these purposes; however, the efficient control of drug release from this 
platform is still being explored. Moreover, other approaches are applied to modify the 
therapeutic activity of drug molecules, such as their conjugation with polymers. 
In this dissertation, lipids and polymers in combination with PSi, and a polymer-drug 
conjugate, were utilized to fabricate advanced DDS by bulk methods or using the 
microfluidics technology.
The specific objectives of this dissertation are:
1. To investigate the loading and release properties of drugs with different solubility 
characteristics into PSi and further develop protective lipid- and polymer-based
structures to achieve controlled drug release. (I?III)
2. To evaluate different modalities of the microfluidics technology for the fabrication 
of PSi-based micro- and nano-composites, including single and double emulsion 
droplet microfluidics, as well as mixing-based microfluidics. (I?III)
3. To develop a smart PSi-based hybrid nanocomposite for antitumoral applications 
with triggered drug release and stealth properties, and for reduced macrophage 
detection in vitro. (III)
4. To explore other methods for the drug loading and preparation of multi-stimuli 
responsive DDS based on a polymer-drug conjugate, including ligands for active 
targeting, and to test their potential for antitumoral applications in vitro. (IV)
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4 Experimental
4.1 Fabrication of glass capillary microfluidic chips (I-III)
4.1.1 Single emulsion flow-focusing (I) and nanoprecipitation co-flow (III) 
glass capillary devices
The microfluidic co-flow and flow-focusing devices were made by assembling borosilicate 
glass capillaries on a glass slide. One end of the cylindrical capillary (World Precision 
Instruments, Inc.), with inner and outer diameters of around 580 and 1000 μm respectively, 
was tapered using a micropipette puller (P-97, Sutter Instrument Co., USA) to a diameter of 
20 ?m; this diameter was further enlarged to ~80 μm by carefully sanding the tip. This 
cylindrical tapered capillary was inserted into a square capillary with inner dimension of 
around 1000 μm (Vitrocom, USA), and coaxially aligned with it. A transparent epoxy resin 
(5 minute? Epoxy, Devcon) was used to seal the capillaries where required. For the single 
emulsion flow-focusing device, the collection capillary was treated with 2-
[methoxy(polyethyleneoxy)propyl]trimethoxy silane, to render a hydrophilic tip and 
prevent wetting of the oil phase on the wall of the capillary. The fluids were injected 
separately into the microfluidics device through polyethylene tubes attached to syringes at 
constant flow rates, controlled by automatic injection pumps (PHD 2000, Harvard 
Apparatus, USA).
4.1.2 Double emulsion glass capillary device (II)
The double emulsion glass capillary device consisted of two cylindrical capillaries of inner 
and outer diameter of 580 and 1000 μm, tapered and carefully sanded to a tip diameter of 
80 and 120 μm for injection and collection, respectively, inserted into the opposite ends of 
a square capillary of inner diameter 1000 μm (II). An additional capillary inserted into the 
injection capillary allowed the inner water and middle oil phases to co-flow within the 
injection capillary. The injection capillary was hydrophobically pre-treated with n-
octadecyl-trimethoxy silane, to favor the contact of the middle oil phase with its wall; and 
the collection capillary was pre-treated with 2-[methoxy(polyethyleneoxy)propyl]-
trimethoxy silane to render a hydrophilic tip in order to prevent wetting of the oil shell of 
the emulsion on the wall of the collection capillary. The fluids were injected separately into 
the microfluidic device through polyethylene tubes attached to syringes at constant flow 
rates controlled by automatic injection pumps.
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4.2 Fabrication of the DDS (I-IV)
4.2.1 Fabrication of PSi micro- and nano-particles (I-III)
PSi MPs were prepared by anodizing a Si wafer (100) of p+-type with resistivity values of 
0.01‒0.02 Ω cm in a HF (38%):ethanol mixture (HF:EtOH 1:1, v:v) using a current density 
of 50 mA/cm2 for 40 min, in order to obtain a porosity of ~65%. [85]. PSi MPs were
produced by dry ball milling (Pulverisette 7, Fritsch GmbH) in an agate grinding jar and the 
particle size fraction of 1 to 38 μm was sorted by wet sieving with ethanol. The MPs were 
then immersed in a HF:EtOH solution to remove the oxidized surface layer and refresh the 
surface hydride species, and further dried at 65 °C for several hours to evaporate the 
electrolyte [88]. In order to improve the stability of the PSi surface towards oxidation, PSi 
MPs were thermally hydrocarbonized by placing the MPs in a quartz tube under continuous 
N2 flow (1 L/min) and acetylene flush (1 L/min) for 15 min, and thermally treated in an 
oven for 10 min at 500 °C. Then the sample was cooled down at room temperature under a 
N2 flow [77, 85].
Alternatively, PSi NPs were produced by three current pulses, the first of which is 
common to the production of the MPs, to render a porosity of the Si wafer of 65%. The 
second consisted of a shorter and higher current pulse to produce a highly porous and 
mechanically fragile layer. The third was a zero-current pulse to remove possible electrolyte 
concentration gradients created in the pores during the high current pulse. Subsequently, the 
porous films were dried and thermally hydrocarbonized following the same protocol as the 
one described for the MPs. Then the PSi film was ball milled using liquid to improve the 
grinding efficacy. The liquid used was 1-decene, which reduced the oxidation of the non-
thermally hydrocarbonized surfaces produced during ball milling due to the high grinding 
forces, which created enough heat to render the thermal hydrosilylation of aliphatic alkenes 
exposed [73, 85].
4.2.2 Single emulsion-based fabrication of solid lipid microcomposites
(SLMCs) (I)
The THCPSi‒solid lipid microcomposites (THCPSi‒SLMCs) were produced with the 
single-emulsion glass-capillary microfluidic flow-focusing device described in the Section 
4.1.1 (I). The inner oil phase consisted of stearic acid (20 mg/mL, w/v) and egg 
phosphatidylcholine (40 mg/mL, w/v) dissolved in ethyl acetate, and bearing THCPSi MPs
(10 mg/mL) that were dispersed by continuous stirring. The outer water phase consisted of 
a Poloxamer 188 aqueous solution (1%, w/v), which efficiently stabilized the oil/ water
interface. The inner oil phase was pumped through the inner capillary at a rate of 2 mL/h 
and focused by the outer water phase pumped in the opposite direction at 40 mL/h, which 
ultimately broke-up the oil phase in droplets, induced by the shear forces. The SLMCs were 
prepare following exactly the same procedure, but without THCPSi MPs in the inner phase.
The SLMCs and THCPSi‒SLMCs produced were collected and the organic solvent from 
the inner oil phase removed by placing the particles in a water bath at 60 °C for 30 min. 
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Lastly, all the collected MPs or microcomposites were solidified on ice for following
characterization.
Drug loaded THCPSi MPs and THCPSi‒SLMCs (I)
Different drugs were loaded into the THCPSi MPs using an immersion method [64]. For all 
the four drugs tested, a drug concentration of 30 mg/mL at a ratio of 3:1 (drug:THCPSi MPs
w:w) and loading time of 2 h, were used. Methotrexate was dissolved in phosphate buffer 
(pH 8.0), ranitidine was dissolved in an ethanol:water solution (1:1), and both furosemide 
and fenofibrate were dissolved in acetone. After the loading, all the suspensions were 
centrifuged at 10000 rpm (5415D, Eppendorf, Germany) for 3 min and the supernatant 
removed with the excess of free drugs. Thereafter, drug-loaded THCPSi MPs were used to 
prepare the THCPSi‒SLMCs with the microfluidics flow-focusing device.
4.2.3 Double emulsion-based fabrication of PSi?lipid vesicles (II)
To fabricate lipid-stabilized double emulsion drops with ultrathin shells and simultaneously 
encapsulate THCPSi MPs within their cores, we used the double emulsion glass-capillary 
microfluidic device described in Section 4.1.2. The inner water phase containing the 
THCPSi MPs with typical sizes of the order of 15 ?m, was pumped into the innermost 
capillary inserted in the injection capillary. To facilitate the dispersion of the THCPSi MPs,
they were pre-wetted with ethanol and suspended into an aqueous solution that contained 8
wt-% PEG (6 kDa) and 2 wt-% polyvinyl alcohol (PVA, 13?23 kDa) at a final concentration
of 3 mg/mL. The suspension was sonicated and poured into a syringe together with a 
magnetic bar that allowed vigorous shaking of the suspension, thereby avoiding MP
aggregation and sedimentation during the injection of the suspension within the microfluidic 
chip. The middle oil phase containing 4.6 mg/mL of 1,2-dioleyl-sn-glycero-3-
phosphocholine (Avanti) was dissolved in a mixture of chloroform and hexane at a volume 
ratio of 1:1.8, containing 0.25 mol-% of 1,2-dioleyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (DHPE-Rh Molecular Probes) to fluorescently label the 
lipid bilayer, which was then pumped through the hydrophobically treated injection 
capillary, co-flowing with the inner water phase. At the tip of the innermost capillary 
inserted on the injection capillary large plug-like water drops containing the THCPSi MPs
were formed, which were broken-up at the tip of the injection capillary into double emulsion 
drops by the shear forces induced by the outer water phase consisting of a 10 wt-% PVA 
(13?23 kDa) aqueous solution. The collection capillary was hydrophilic, which prevented 
the wetting of the oil shell of the emulsion on the wall of the collection capillary.
Importantly, this microfluidic approach provided 100% encapsulation efficiency since
the particles in the inner water phase ended-up in the cores of the double emulsions as shown 
in publication II.
The double emulsion droplets were collected in an aqueous solution of sucrose with the 
same osmolarity as the inner water phase (100 mOsm/L) to avoid any osmotic 
destabilization of the double emulsion droplets. Under these conditions, the chloroform in 
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the middle oil phase easily evaporated from the shell of the double emulsions, thereby 
increasing the ratio of hexane, which is a poor solvent for the lipids in the oil shell of the 
double emulsion. This reduction in solvent quality induced the attraction between the two 
monolayers of lipids at the o/w interfaces of the double emulsion, which lead to the
dewetting of the hexane from the inner cores of the double emulsion droplets, and ultimately 
resulted in the formation of the lipid bilayer. The dewetting process occurred in about two
minutes [163]. The small amount of residual solvent present in the vesicles after dewetting 
remained concentrated in a very small region of the bilayer, allowing the bilayer to behave 
similarly to vesicles produced by conventional approaches [163]. Moreover, the organic 
solvent evaporated further in the next days.
Drug loaded THCPSi MPs and THCPSi‒lipid vesicles (II)
The THCPSi MPs were loaded with piroxicam, which belongs to the Biopharmaceutical 
Classification System class II, i.e., the dissolution rate is the limiting factor in the
permeability across biological membranes. To load piroxicam, an immersion method was 
used [27]. The THCPSi MPs were stirred in an acetone solution of piroxicam at 15 mg/mL 
for 2 h. Then, the suspension was centrifuged at 11,300g for 4 min and the pellet was washed 
3 times with 0.5 mL of MilliQ-water. The water allowed to remove the excess of piroxicam 
from the surface of the particles, while avoiding a premature release of the drugs from the 
pores. Finally, the loaded MPs were suspended into the inner water phase and the production 
proceeded as described previously.
4.2.4 Nanoprecipitation-based fabrication of PSi‒Polymer composite (PSi‒
PC) (III)
The PSi−PC was produced by on-chip nanoprecipitation using the flow-focusing glass 
capillary device described in Section 4.1.1 (III). The inner fluid was prepared by mixing the 
PSi NPs with the polymers in solution. Poly(ethylene) glycol-block-polylactide methyl ether 
(PEG‒PLA) (0.625 mg) was dissolved in 7.5 mL of ethanol, and poly(ethylene) glycol)-
block-poly(L-histidine) (PEG‒PHIS) (1.875 mg) was dissolved in 2.5 mL of 0.1 M of 
hydrochloric acid containing 0.3 mM of citric acid and 0.2% (w/v) of F127. PSi was added 
to the aqueous solution and dispersed by 30 seconds tip sonication at 30% amplitude. Then,
it was mixed with the ethanolic solution and sonicated again for 30 seconds at 30% 
amplitude. The final concentration of PSi NPs was 100 μg/mL. The outer fluid consisted of 
a F127 in Milli-Q water solution (0.2% w/v) adjusted to pH 12.8. Both fluids were pumped 
inside the microfluidic chip at a rate of 10 and 100 mL/h for the inner and outer fluids, 
respectively, and forced to co-flow and rapidly mix inside the microfluidic channels. While 
both the fluids were mixed, the solvent quality was decreased, leading to the 
nanoprecipitation and formation of the PSi−PC. The empty compound micelles were 
obtained by the exact same procedure, without including PSi NPs into the inner phase.
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Drug loaded PSi NPs and PSi‒PC (III)
Sorafenib (SFN), a drug that inhibits cell proliferation and angiogenesis in tumors, was 
loaded into the PSi NPs using an immersion method [64]. The drug was dissolved in acetone 
(2 mg/mL) and PSi was added to the solution in a ratio of SFN:PSi of 6.7:1. The suspension 
was stirred for 90 min to allow the loading of the drug within the pores of PSi. After stirring, 
the suspension was centrifuged at 15000 rpm for 5 min and the supernatant with excess of 
free drug was removed. Consequently, the particles were washed with 20% (v/v) acetone in 
Milli-Q water (500 μL) to wash out the free drug on the surface of the PSi NPs. The samples 
were then centrifuged, the supernatant removed, and the pellet resuspended in the medium 
of interest. Subsequently, the loaded PSi NPs were used to produce the SFN-loaded 
nanocomposites
4.2.5 pH-switch nanoprecipitation of IO@PNP (IV)
The NPs were produced by an organic solvent-free pH-switch nanoprecipitation method
[273]. For that, methoxy-terminated PEG‒PHIS (mPEG‒PHIS) and amino-terminated 
PEG‒PHIS (NH2-PEG‒PHIS) were dissolved to a concentration of 10 mg/mL in 10 mM of 
acetic acid. Both the solutions were subsequently mixed in a ratio of 9:1, mPEG‒PHIS to 
NH2-PEG‒PHIS. To this polymeric solution, PEG-coated SPION with a size of 5 nm 
(Sigma-Aldrich) were added to a final concentration of 100 μg/mL. Thereafter, the polymer 
solution containing SPION was added dropwise to an equal volume of Na2HPO4 (50 mM)
and citric acid (25 mM) buffer (pH 5) under stirring for 30 min. Then, the NPs were pelleted 
by centrifugation for 5 min at 13.200 rpm and resuspended in 10 mM of 4-(2-
Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4.
Fabrication of IO@PNP-DOX (IV)
For the preparation of the polymer-drug conjugate-based IO@PNP, first the DOX free base 
was conjugated to the C-terminal side of mPEG‒PHIS by an 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide/N-Hydroxysuccinimide (EDC/NHS) coupling 
reaction (IV), linking both the molecules through an amide bond. The mPEG‒PHIS-DOX
produced was dissolved in 10 mM of acetic acid (10 mg/mL) and mixed with NH2-PEG‒
PHIS also dissolved in 10 mM of acetic acid (10 mg/mL) in a ratio of 9 to 1. Then the 
IO@PNP-DOX were produced as described above.
In order to follow the intracellular fate of IO@PNP-DOX in vitro, NH2-PEG‒PHIS was 
used instead of mPEG‒PEG‒PHIS, to attach Alexa fluor 647 (AF) and DOX 
simultaneously. First, NH2-PEG‒PHIS was labelled with NHS-AF, by direct coupling in 10 
mM of 2-(N-morpholino) ethanesulfonic acid (MES) buffer pH 6 (2 mg/mL) for 12 h. The 
product was purified by centrifugal filtration using a spinning tube with a membrane with a 
molecular weight cut-off of 3 kDa (Spectrum Laboratories, Inc.). The washing process was 
repeated five times using deionized water. Then, DOX was conjugated to AF-NH-PEG‒
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PHIS as described above. NPs were prepared with the resulting AF-NH-PEG‒PHIS-DOX, 
rendering the formation of IO@AF-PNP-DOX.
Decoration of the NPs with iRGD homing-peptide (IV)
The iRGD cyclic peptide was conjugated with the amine groups of NH2-PEG‒PHIS present 
on the surface of either IO@PNP or IO@PNP-DOX using a cross-linker, which represented 
10% of the total polymer conferring the NPs. The cyclic peptide iRGD fluorescein 
isothiocyanate-labeled (FITC-Ahx-CCRGDKGPDC, C2-C10), was purchased from United 
BioSystems Inc., and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-
carboxylate (Sulfo-SMCC), and the cross-linker containing NHS and maleimide reactive 
groups, was purchased from (Thermo Fisher Scientific Inc.). First, the NPs were suspended 
after centrifugation in 10 mM of HEPES solution (pH 7.5) to a concentration of 5 mg/mL, 
equivalent to 0.5 mg/mL of the amine terminated polymer. A 10 mg/mL solution of sulfo-
SMCC was freshly prepared in the same medium, added to the NPs’ suspension in a 60 
molar excess with respect to the amine terminated PEG‒PHIS, and stirred for 30 min. Then, 
the non-reacted crosslinker was washed out by centrifugation, followed by dispersion of the 
NPs in 10 mM of HEPES solution (pH 7.5) to a concentration of 5 mg/mL. Next, 20 molar 
excess of the peptide, with respect to the amine terminated PEG‒PHIS, was added to the 
NPs’ suspension. The reaction was allowed to proceed for 30 min and then the IO@iRGD-
PNP and IO@iRGD-PNP-DOX were collected and washed twice with the same medium.
4.3 Characterization of the DDS (I-III)
The properties of THCPSi MPs (I and II) were characterized with N2 sorption at 77 K using 
TriStar 3000 gas sorption apparatus (Micromeritics Inc., Norcross, USA). The specific 
surface area and pore volume was calculated from the isotherm using the Brunauer-Emmett-
Teller theory [274]. The average pore diameter was estimated using the obtained values of 
the specific surface area and the total volume at a relative pressure of p/p0 = 0.97 by
assuming the pores as cylindrical. The particle size distribution of the THCPSi MPs after 
sieving was determined using Sympatec Helos laser diffractometer, equipped with a Cuvette 
wet disperser system (Sympatec GmbH, Clausthal-Zellerfeld, Germany). For the 
measurements, the MPs were dispersed in ethanol and stirred at 400 rpm. 
The morphology and size of all the drug carriers developed in this project were also 
studied. According to the size range of the carrier, either confocal fluorescence microscopy 
(I and II) or light scattering and electron microscopy (III and IV), were used to address 
these features.
The microcarriers (I and II) were imaged by confocal fluorescence microscopy and the 
size of the MPs analyzed based on these images (Image J). Thereupon, THCPSi MPs
encapsulated within the solid lipid MPs (I) were fluorescently labelled with Rhodamine 123 
(Sigma-Aldrich) in order to ease the visualization of the THCPSi MPs within the lipidic 
structure using confocal fluorescence microscopy. In the case of the THCPSi‒lipid vesicles
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(II), the membranes of the vesicles were fluorescently labeled with DHPE-Rh (Molecular 
Probes). THCPSi MPs and THCPSi?SLMCs were suspended in the aqueous outer phase, 
and the PSi‒lipid vesicles were suspended in a 100 mOsm/ L sucrose water solution, 
collected onto a glass slide and then observed by Leica SP2 inverted confocal microscope 
with a HCX Plan Apochromat 63?/1.2-0.6 oil immersion objective (Leica Microsystems, 
Germany) equipped with argon (488 nm) and DPSS (561 nm) lasers.
The size and polydispersity index (PDI) of the nanocarriers was studied by light 
scattering. PSi‒PC (III) were suspended in Milli-Q water adjusted to pH around 7.4 to 
preserve the NPs’ structure and analyzed by multiangular dynamic light scattering (DLS) 
using a Brookhaven Instruments BI-200SM goniometer, with the detector set at different 
scattering angles, i.e., 45°, 60°, 90°, and 135°. The polydispersity was estimated using the 
2nd order cumulant fit to represent the size distribution width of the NPs’ population [275].
IO@PNP (IV) were dispersed in 10 mM HEPES (pH 7.5) prior to analyzing their size and 
PDI by DLS with a detector set at an angle of 173°.
The morphology of the nanocarriers was identified by transmission electron microscopy 
(TEM, Tecnai 12, FEI Company, USA) at an acceleration voltage of 120 kV. In addition, 
the nanocarriers were imaged using SEM (Quanta 250 FEG; FEI Company, USA) (II, III, 
and IV).
For the last work of this thesis (IV) the amount of SPION encapsulated in the polymeric 
NPs (IO@PNP) and the magnetic properties were evaluated. The amount of SPION 
encapsulated in IO@PNP was quantified by UV absorbance (UV-1600 PB 
Spectrophotometer, VWR). About 1 mg of IO@PNP was prepared and the NPs pelleted, 
washed with 10 mM of HEPES solution (pH 7.5) to remove free SPION, and finally the 
polymer was dissolved in 10 mM of acetic acid. Spectra of PEG‒PHIS and SPION in 10 
mM of acetic acid were obtained independently, and a calibration curve of the absorbance 
of different concentrations of SPION at 290 nm was performed. Then, the spectra of the 
solution was obtained and the amount of SPION calculated. Consequently, a suspension of 
IO@PNP was prepared and put in a 6-well plates and the magnetic NPs were guided and 
accumulated around the magnetic field of the magnet. In addition, the hysteresis loop of the 
SPION and IO@PNP was determined using a magnetometer (MicroMag 3900 VSM; Lake 
Shore Cryotronics, Inc.). For this, 36.7 μg of SPION or 3.96 mg IO@PNP containing the 
same amount of SPION were dried and placed in a gelatin capsule for the measurements. 
The magnetic moment (A m2) obtained versus the applied magnetic field (T) was 
normalized with the amount of SPION in the sample and corrected for dia/paramagnetic 
component in order to obtain the magnetization value (Am2/kg)
In addition, the amount of iRGD conjugated to the IO@PNPs was quantified by 
fluorescence (IV). For this, a calibration curve of the FITC-labelled iRGD dissolved in 10 
mM of HEPES (pH 7.5) was made and the fluorescence intensity value of the IO@iRGD-
PNP in the same buffer medium was interpolated using the calibration curve.
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4.4 Loading degree and drug release studies (I-III)
The PSi micro- and nano-particles used in this thesis (I?III) were loaded with various drugs 
by an immersion method [64], and the drug-loaded PSi particles were used to produce the 
composites, as described in the Sections 4.2.1, 4.2.2, and 4.2.3. However, for the last work 
presented in this thesis (IV), the loading of the drug was achieved by the production of NPs
based on a polymer-drug conjugate (Section 4.2.5).
4.4.1 Loading degree (I-III)
The loading degree of the bare PSi particles and the PSi composites was assessed by 
disassembling the polymers or lipids encapsulating the PSi particles when applicable, and 
completely releasing the drug payload from PSi particles with a suitable solvent for the 
release of the drug. The drug was then analyzed by high pressure liquid chromatography 
(HPLC) and the drug loading calculated as the percentage in weight of the drug to the 
carrier.
The conjugation efficiency of DOX to the mPEG‒PHIS chains that were further used to 
produce IO@PNP-DOX (IV) was evaluated by analyzing the fluorescence intensity of DOX 
in dymethylsulfoxide (DMSO). For that, a calibration curve of DOX free base in DMSO 
was prepared and the intensity values of the DOX-polymer conjugates interpolated in the 
calibration curve. The conjugation efficiency of DOX free base to mPEG‒PHIS was 40% 
(mol/mol). Subsequently, mPEG‒PHIS-DOX and NH2-PEG‒PHIS in a 9:1 ratio were used 
to produce IO@PNP-DOX, yielding a final DOX loading of 36% (mol/mol)
(polymer/DOX)
4.4.2 In vitro drug release (I-IV)
In vitro drug release was assessed for the bare PSi particles and the corresponding 
composites (I?III). For studies I and II, the drug loaded, the THCPSi MPs, THCPSi‒
SLMC, and THCPSi?lipid vesicles were added into dialysis bags with a molecular weight 
cut off of 1 kDa, and placed in the release buffers maintaining sink conditions for the drug.
For the study III, PSi‒PC were directly added into the release medium. In all cases (I?III),
a certain volume of the release medium was withdrawn at each timepoint to analyze the 
drug concentration by HPLC, and the withdrawn medium was then replaced.
The release of the four model drugs loaded into the THCPSi MPs and THCPSi‒SLMCs 
(I) was determined after solvent evaporation from the SLMC structure, by placing the 
samples into a dialysis bag and immersing them into buffers with pH values of 1.2, 5.0, and 
7.4, while shaking at 100 rpm and 37 °C. For the release of fenofibrate Tween-80 (1%, w/v) 
was added to the release media due to the low solubility of the drug.
Similarly, the release of piroxicam from THCPSi MPs and THCPSi‒lipid vesicles (II)
placed in the dialysis bags was studied in buffers at pH 7.4 and 6, while shaking at 45 rpm 
and 37 °C.
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In the case of SFN-loaded PSi NPs (SFN-PSi) and PSi‒PC (III), samples were added 
directly to the release medium. Owing to the very poor water solubility of SFN, dissolution 
was aided by adding to the release medium fetal bovine serum (FBS) proteins [121],
therefore hindering the use of dialysis bag, which does not allow the free diffusion of the 
proteins. The release of SFN was analyzed in human plasma (pH 7.4), and buffers pH 6.8 
and 5.5 enriched with 10% FBS, while stirring at 500 rpm and 37 °C.
The release and delivery of DOX (IV) was assed intracellularly using IO@AF-PNP-
DOX. Amide bonds are known to be chemically stable [276], thus enzymatic cleavage of 
the bond was necessary to release the DOX from the polymer conjugate, which can be done 
by the lysosomal enzyme cathepsin-b [277]. Accordingly, the drug-NPs were incubated 
with a prostate cancer cell line, PC3MM2, and the intracellular fate of the NPs observed by 
confocal fluorescence microscopy for 1, 3, 6, 10, and 24 h. The cell nuclei were stained after 
fixation with 4, 6-diamidino-2-phenylindole (DAPI) for 3 min, followed by five times 
washing with Hank’s balanced salt solution‒HEPES (HBSS‒HEPES) solution. More 
details about cell culturing and incubation are given in the Section 4.6.3.2.
4.5 Human plasma stability of nanocarriers (III and IV)
PSi NPs, PSi−PC (III) were dispersed in phosphate buffer saline (PBS) (150 μL) and added
to human plasma (1 mL) (obtained from anonymous donor from the Finnish Red Cross 
Blood Service) at a concentration of 150 μg/mL. The suspension was stirred at 37 °C, and 
the samples were withdrawn after 1, 2, 5, 10, 20, 30, 60, 90, and 120 min. The samples were 
transferred and diluted into a folded capillary cell (Malvern Instruments) and the size, PDI,
and ζ-potential were measured by DLS.
4.6 In vitro cell-based studies (I-IV)
4.6.1 Cell lines and cell culture (I-IV)
Human colon adenocarcinoma Caco-2, mucus-secreting intestinal cells HT29, and 
macrophage cells RAW 264.7 were obtained from American Type Culture Collection 
(USA); and the human prostate cancer cells PC3MM2 were kindly provided by Prof. Akseli 
Hemminki (Faculty of Medicine, Biomedicum Helsinki, University of Helsinki, Finland).
All the cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% FBS, 1% non-essential amino acids, 1% L-glutamine, penicillin 
(100 IU/mL) and streptomycin (100 mg/ml). The cell cultures were kept in a standard 
incubator (16 BB gas, Heraeus Instruments GmbH, Germany) at 37 °C in an atmosphere of 
5% CO2 and 95% relative humidity. The growth media was changed every other day for all 
the cell lines until the day of the experiments, and the subculturing performed at 80% 
confluency using trypsin?PBS?EDTA solution.
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4.6.2 Cytotoxicity (I?IV)
The in vitro cytotoxicity of the particles (I and II) and the drug loaded particles (III and IV)
was assessed by an ATP-based cell viability kit, according to the manufacturer’s 
specifications. Briefly, the cells were seeded in 96-well plates (Corning Inc., USA) at a 
concentration of 5×105 HT-29 cells/mL, 2.5×105 Caco-2 cells/mL, and 1×105 PC3MM2 
cells/mL; and allowed to attach overnight. Next, the medium was replaced with different 
concentrations of particles dispersed in 1× HBSS‒HEPES (I, II and IV) or DMEM enriched 
with 10% FBS (III), to allow the release of SFN. A positive (1% Triton X-100 solution)
and negative control (HBSS–HEPES buffer solution) were included in each 96-well plate.
After predetermined incubation times, the NPs were removed from the wells and washed 
with fresh HBSS–HEPES buffer. Then, 100 μL of CellTiter-Glo® reagent assay (Promega 
Corporation, USA) were added to each well and the luminescence analyzed with a 
Varioskan Flash Multimode Reader (Thermo Fisher Scientific, USA). All the experiments 
were performed at least in triplicate (n ≥ 3).
4.6.3 Cell‒particle interactions and intracellular trafficking (III and IV)
4.6.3.1 Flow cytometry analysis (III and IV)
The internalization of NPs (III and IV) by RAW 264.7 (III), PC3MM2 (IV), and EA.hy926 
cells (IV) was studied using flow cytometry. The cells were seeded in 6 well-plates (2 mL) 
at a concentration of 2.5×105 cells/mL, and incubated overnight at 37 °C to allow the 
attachment of the cells to the well. Next, the medium was removed from the wells and 
washed once with HBSS‒HEPES buffer solution. About 1 mL of different concentrations 
of Alexa Fluor 488 (AF 488) (III) and Alexa Fluor 647 (AF 647) (IV)-labeled NPs dispersed 
in DMEM supplemented with 10% FBS (III) or HBSS‒HEPES buffer solution (IV) were 
added to each well. In each experiment, a negative control of cells without treatment, 
incubated either with DMEM 10% FBS or HBSS‒HEPES was used for comparison.
All the samples were incubated for 3 h at 37 °C, whereupon the medium was removed 
from the wells and washed three times with HBSS‒HEPES to remove any free NPs not 
associated with the cells. Finally, the cells were harvested by incubating them with 
tryspsin?PBS? ethylenediaminetetraacetic acid (trypsin‒PBS‒EDTA) for 5 min at room 
temperature, after which the cells were centrifuged for 5 min at 900 rpm, and the 
extracellular fluorescence of the AF 488 NPs (III) quenched with trypan blue. Then, the 
cells were washed and the medium replaced with 300 μL of PBS with EDTA (5 mM). NP‒
cell internalization and association were quantified by flow cytometry (Galios Flow 
Cytometer; Beckman Coulter, Inc.; laser 642 nm) and the data was post-processed using the 
software FloJo X (FlowJo, LLC).
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4.6.3.2 Confocal fluorescence microscopy analysis (III and IV)
The NP’s intracellular localization (III and IV), lysosomal escape (IV), and DOX 
intracellular release (IV), were studied by confocal fluorescence microscopy with RAW 
264.6 (III) and PC3MM2 cells (IV). For this, the cells were seeded in an 8-chamber slide 
(Nunc Lab-Tek II Chamber Slide System, Thermo scientific, Inc., USA) at a concentration 
of 2.5×105 cells/mL (200 μL/chamber), and incubated overnight at 37 °C to allow the 
attachment of the cells. Next, the medium was removed from the chamber and replaced with 
200 μL of a 100 μg/mL suspension of FITC-labeled (III) and AF 647-labeled (IV) NPs in 
DMEM supplemeted with 10% FBS (III) or HBSS‒HEPES buffer solution (IV). A negative 
control of the cells without treatment, incubated with either DMEM containing 10% FBS 
or HBSS‒HEPES buffer solution was included in each chamber.
The NPs were then incubated with the cells, whereupon the NP suspensions were 
removed and the NPs not associated with the cells washed out with HBSS‒HEPES buffer 
solution. Then, the different cell components were stained according to the needs of each 
study. For RAW 264.7 cells (III), the cell membrane was stained with CellMask Deep Red 
(Life Technologies, USA), according to the manufacturer’s instructions. In the case of 
PC3MM2 (IV), either the lysosomes to study the lysosomal escape or the nuclei to study 
intracellular release of DOX, were stained. The lysosomes were stained by incubating the 
cells with LysoTracker Red for 30 min at 37 °C. The nuclei were stained with DAPI after 
fixation of the cell culture, by incubating the cells with 300 μM DAPI in 1× PBS for 3 min. 
All the cell cultures were fixed with 2.5% glutaraldehyde solution in HBSS‒HEPES buffer 
solution for 30 min at room temperature followed by five times washing with HBSS‒
HEPES buffer solution. PBS was finally added to the chambers and then the cells were 
visualized with a confocal fluorescence microscope (Leica inverted confocal microscope 
SP5 II HCS A) using HeNe (633 nm), DPSS (561 nm), Ar (488 nm), and UV-diode (405 
nm) as the laser sources, and a water immersion objective HCX PL APO 63×.
4.7 Hemotoxicity (IV)
RBCs were purified from human blood extracted from anonymous donors at the Finnish 
Red Cross Blood Service. Blood was stabilized with heparin and used within 2 h.
For the isolation of RBCs, 5 mL of the blood sample were mixed with 10 mL of sterile 
Dulbecco’s PBS pH 7.4 (D-PBS) and centrifuged for 6 min at 3000 rpm in order to separate 
the RBCs from the serum. RBCs were then washed five times, and finally diluted twenty 
times with D-PBS. About 60 μL aliquots of this suspension were added to 240 μL of the 
IO@PNP and IO@iRGD-PNP to a final concentration of 25, 50, 100, and 200 μg/mL. The 
suspension was mixed and incubated for 1, 4, 6, and 24 h. Subsequently, at each time point, 
the sample was homogenized and 50 μL were transferred to an Eppendorf. The sample was 
then centrifuged for 3 min at 13000 rpm and the supernatant transferred to a 96-well plate 
to measure the absorbance intensity of hemoglobin at 577 nm using a microplate reader. D-
PBS and water were used as negative and positive controls, respectively. 
For the timepoint corresponding to 4 h, the morphology of the RBCs was also 
investigated by SEM. For this, the pellet of RBCs was re-dispersed in 2.5% glutaraldehyde 
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and incubated for 1.5 h in order to fix the membrane of the cells. After the incubation time, 
the RBCs were washed three times with D-PBS and post-fixed in 1% osmium tetraoxide in 
0.1 M of sodium cacodylate buffer (pH 7.4) for 1 h. The cells were then dehydrated in 
increasing concentrations of 50, 70, 96, and 100% of ethanol for 5, 10, 20, and 15 min, 
respectively [278]. Finally, the cell’s suspensions were dropped onto plastic coverslips, 
dried, and sputter coated with platinum prior to SEM imaging.
4.8 Ex vivo studies (IV)
All experimental protocols with animals were approved by the Laboratory Animal Center 
of the University of Helsinki and the National Animal Experiment Board of Finland, in
conformity with the EU’s Guidelines for Accommodation and Care of Animals, following 
the Act (497/2013) and the Decree (564/2013) on Animal Experimentation approved by the 
Finnish Ministry of Agriculture and Forestry and the EU Directive (2010/63/EU). Adult 
Wistar rats were sacrificed and the liver and kidney removed and kept in 1× PBS placed in 
ice. The tissues were then cut into small pieces and the RBCs were washed out with cold 1×
PBS. The tissues were mechanically disaggregated by mincing and forcing them through a 
70 μm cell strainer to a 6 well-plate with 1× PBS placed in ice. The cell suspensions were 
transferred to a 15 mL Falcon tube and filled-up to 10 mL with cold 1× PBS. Subsequently, 
the suspensions were centrifuged at 900 rpm for 5 min at 4 °C and the supernatant discarded 
in order to remove any remaining RBCs from the surface of the pellet. The liver or kidney 
cells were then resuspended in HBSS‒HEPES buffer solution, containing 10% of FBS, and 
then the cells were counted. The cells were seeded in 96-well plates (4×105 cells/mL, 50 
μL), and 50 μL of the particles prepared at different concentrations, ranging from 50 to 200 
μg/mL in HBSS‒HEPES buffer solution were added to each well. After 6 h of incubation, 
the ATP activity was assessed with CellTiter-Glo® Reagent (Promega Corporation, USA), 
according to the manufacturer’s protocol. The luminescence was measured with a Varioskan 
Flash Fluorometer (Thermo Fisher Scientific, USA). All the experiments were performed 
at least in triplicate (n ≥ 3).
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5 Results and discussion
5.1 Single-emulsion microfluidic templated THCPSi MPs‒SLMCs
for sustained drug delivery (I)
In the first work of this thesis, it was developed a single-emulsion microfluidics production 
method of THCPSi MPs encapsulated in a solid lipid matrix, which allowed to obtain stable 
and reproducible composites to overcome the major drawbacks that THCPSi particles
present for drug delivery applications, such as premature drug release and poor aqueous 
stability. The solid lipid matrix efficiently capped the pores of the THCPSi MPs, controlling 
the release of both hydrophilic and hydrophobic molecules while improving the surface 
properties of the THCPSi MPs by enhancing their stability and biocompatibility.
5.1.1 Characterization and cytocompatibility
THCPSi MPs presented irregular shapes and an average particle size of 16 ?m measured by 
a laser diffractometer when dispersed in ethanol. However, when dispersed in aqueous 
medium (Figure 8a), their size looked larger. This phenomenon could be ascribed to the 
poor dispersibility of PSi MPs in aqueous medium and their tendency to aggregate as a 
result of hydrophobic interactions [28].
Thereafter, the successful encapsulation of THCPSi MPs within the solid lipid matrix
was confirmed by fluorescently labelling the THCPSi MPs (Rhodamine 123-labelled PSi 
MPs) and observing the obtained composite by confocal fluorescence microscopy (Figure
8a). The composite had a typical diameter of about 24.9 μm, with a variation coefficient of 
15.4%, and were around 17.8% smaller than the droplets used as templates due to the solvent
evaporation process. In addition, unlike THCPSi MPs, the microcomposites presented 
spherical shape and outstanding dispersibility, owed to the reduction of the surface 
hydrophobicity of THCPSi MPs.
As a result of their micrometric size, these vehicles could be possibly applied for oral 
drug delivery, and thus, their cytocompatibility with GI tract related cancer cell lines, Caco-
2 and HT-29, was also evaluated (Figure 8b). THCPSi MPs incubated with Caco-2 cells 
demonstrated a concentration-dependent cytotoxic effect for 4 and 24 h incubation, with
decreased cell viability of 40% as the dose of THCPSi MPs increased from 100 to 2000 
μg/mL. In contrast, HT-29 cells only showed a weak particle dose-dependent viability
towards the bare THCPSi MPs after 4 and 24 h incubation (I). Solid lipid encapsulated
THCPSi MPs demonstrated greatly enhanced cytocompatibility, especially in the case 
Caco-2 cells incubated with the higher doses of the particles tested (2000 and 1000 μg/mL). 
For the concentration of 2000 μg/mL incubated 4 and 24 h, the viability of Caco-2 cells 
incubated with THCPSi MPs compared to THCPSi‒SLMCs increased from ~50 to 90% and 
35 to 80%, respectively.
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Figure 8 Characterization and cytocompatibility of THCPSi MPs and THCPSi‒SLMCs. (a) 
Bright field and confocal fluorescence images of Rhodamine 123-labelled (green) 
THCPSi MPs and THCPSi?SLMCs. (b) Cytotoxicity of THCPSi MPs and THCPSi 
MPs‒SLMCs incubated with GI related cancer cells lines, Caco-2 and HT-29, for 24 
h. Error bars represent the mean ± S.D (n = 4). The levels of significance were set at 
the probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. Copyright © (2013)
American Chemistry Society, reprinted with permission from publication (I).
The cytotoxicity induced by the MPs is a result of their interactions with the membranes 
of the cells, mainly determined by the nature of the surface of the particles [279-282].
Because of the similar zeta-potential values measured for both the bare THCPSi MPs (ca. 
?35 mV) and the microcomposites (ca. ?43 mV), the difference in cell viability cannot be 
attributed to their surface charge properties. Thus, the greater cytotoxicity induced by the 
bare THCPSi MPs may be due to the stronger hydrophobic interactions with the cell 
42
membranes [28, 66, 283] induced by the hydrophobic nature of THCPSi MPs,: the 
formation of large aggregates of MPs, and their irregular shapes. In contrast, the greater 
cytocompatibility observed for the THCPSi‒SLMCs was likely due to the higher 
hydrophilicity and spherical morphology of the SLMCs compared to the THCPSi MPs,
which probably resulted in a decrease in the interactions between the cells and the SLMCs
[284].
5.1.2 Drug loading and release
To evaluate the loading capacity of the microcomposites and their potential to sustain the
release of payloads, four model drugs with different solubilities in aqueous medium were 
selected: fenofibrate and furosemide, which are poorly water-soluble drugs, and 
methotrexate and ranitidine, which present higher water solubility than the former drugs.
The degrees of loading for the four model drugs into the PSi MPs and into the final 
microcomposites are listed in Figure 9. For the bare PSi MPs the drug loading degrees 
varied from about 9% for ranitidine to ~25% for furosemide. These differences can be 
partially ascribed to the different chemical structures and the different solubility 
characteristics of the drugs. The ability of the different loading solutions to wet the surface 
and pores of the PSi MPs might also have contributed to the variation in the degree of the 
drug loaded [285].
Figure 9 Drug loading degrees (%) obtained by the immersion method for THCPSi MPs and
THCPSi?SLMCs after microfluidic fabrication. The levels of significance were set at a 
probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. Copyright © (2013) American 
Chemistry Society, reprinted with permission from publication (I).
For the microcomposites, unlike the THCPSi MPs, the loading degree was lower, mostly 
due to the partial pre-release of the drugs when THCPSi was dispersed in the inner oil phase 
used for the microfluidic preparation of the droplet templates. This decrease was more 
remarkable in the cases of fenofibrate and furosemide, for which approximately half of the
payload was pre-released during the templation. In contrast, for methotrexate and ranitidine, 
only minute amounts of drugs were pre-released during the encapsulation process. These 
differences were due to the different solubility of the drugs in the organic phase, ethyl 
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acetate, which was relatively high for fenofibrate and furosemide, but moderately low for 
methotrexate and ranitidine. These results indicated that a poor solubility of the drug in the 
solvent used as the inner fluid in the microfluidic setup is critical to preserve the degree of 
drug loading into the PSi MPs after their encapsulation within the SLMCs. In addition, the 
resultant microcomposites allowed the incorporation of rather aqueous-soluble drugs in 
their structure, which are usually difficult to load into traditional colloids, such as polymeric 
particles, o/w emulsions or micelles, due to the inherent hydrophobicity of these composites
[286-288].
The release profiles of the four model drugs loaded in the THCPSi MPs (Figure 10) and 
THCPSi‒SLMCs were studied in buffers with pH values of 1.2, 5.0, and 7.4, for simulating 
the physiological conditions of the GI tract. The dissolution rate of the less aqueous soluble 
drugs, fenofibrate (Figure 10a-c) and furosemide (Figure 10d-f), was enhanced when 
loaded in the THCPSi MPs. Furthermore, the dissolution rate of these drugs from the 
THCPSi MPs and THCPSi‒SLMCs was dependent on the pH, showing in both cases similar 
trends, i.e., faster dissolution or release rate at increased pH values. These results can be 
ascribed to the lower solubility of the payloads at lower pH conditions and to the
significantly different properties of the phospholipid matrix at acidic pH conditions (<3),
such as the increased phase transition temperature, gel-phase characteristics, and slight 
alteration of the phospholipid surface charge, which could also contribute to slow down the
release rate of the payloads from the THCPSi‒SLMCs at acidic pH conditions [289, 290].
For methotrexate and ranitidine, the impact of both THCPSi MPs loading and pH-value
on the release profiles was less pronounced than for fenofibrate and furosemide (Figure 
10g?l). For methotrexate, the release rate was only slightly slower at pH 5.0, whereas the 
release rate of ranitidine was independent of pH for all the pH values tested. Regardless of 
the pH-value of the media and the solubility of the four model drugs, the release rate of 
payloads from the microcomposites was always slower than that from the bare THCPSi 
MPs. For example, in the case of fenofibrate at pH 1.2, the time for the release of 50% 
fenofibrate from the THCPSi MPs was about 2.5 h, whereas from the microcomposite it 
was ~7.5 h. More importantly, these microcomposites efficiently reduced the initial ‘burst 
release’ of the drugs observed in the case of the bare PSi MPs, which was more pronounced 
for the aqueous-soluble drugs. For example, ~20% of ranitidine was released from the bare 
THCPSi MPs within the first 5 min, whereas only ~5% was released from the corresponding 
microcomposites, independent on the pH-value tested. 
Therefore, better control over the release of the drugs was achieved with the THCPSi‒
SLMC than with the bare THCPSi MPs, significantly reducing both the in vitro release rate 
of the payloads and also the initial ‘burst release’ of the drugs.
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Figure 10 Release profiles of the payloads from THCPSi MPs and THCPSi?SLMCs. Fenofibrate 
(a, b, and c), furosemide (d, e, and f), methotrexate (g, h, and i), and ranitidine (j, k, 
and l) were loaded into the particles and the release profiles were measured at pH 1.2 
(a, d, g and j), 5.0 (b, e, h and k), and 7.4 (c, f, i and l). The dissolution profiles of pure 
drugs are also shown for comparison. All experiments were conducted at 37 °C. Error 
bars represent the mean ± s.d. (n = 3). Copyright © (2013) American Chemistry 
Society, reprinted with permission from publication (I).
5.2 Double-emulsion microfluidic templated THCPSi MPs‒lipid 
vesicles for sustained drug delivery (II)
In the second study, it was investigated the combination of lipid vesicles with ultra-thin 
membrane around THCPSi MPs in order to overcome the limitation that these vesicles 
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present. The ultra-thin membranes hamper the loading of hydrophobic molecules within, 
and thus, the THCPSi MPs were loaded with a hydrophobic drug and encapsulated in the 
aqueous core of lipid vesicles to provide them with the capacity to load hydrophobic cargo. 
The THCPSi MP‒lipid vesicles were produced by double emulsion microfluidics in a highly 
efficient and reproducible manner.
5.2.1 Microfluidic encapsulation of THCPSi MPs in lipid vesicles and
characterization
THCPSi MPs were encapsulated in the aqueous core of ultra-thin lipid vesicles, with ~100% 
encapsulation efficiency (Figure 11a), rendering THCPSi MP‒lipid vesicles with a 
diameter of 114 ± 8.4 μm (Figure 11b). The lipid bilayer was stained with a fluorescent dye 
for further visualization by confocal fluorescence microscopy (Figure 11c). In addition, the 
THCPSi MPs were observed by SEM (Figure 11d).
Figure 11 (a) Optical microscope image of a typical THCPSi MP‒lipid vesicles production based 
on double emulsion microfluidics. It can be observed that all the THCPSi MPs ended-
up in the inner core of the lipid vesicles. (b) Optical microscope image of THCPSi MP‒
lipid vesicles suspended in an aqueous solution of sucrose. (c) Optical and fluorescence 
confocal overlaid images of a single THCPSi MP‒lipid vesicle. A THCPSi MP is
pointed out by the blue region and the lipid bilayer was stained with a fluorescent dye
(red). (d) SEM micrograph of a THCPSi MP. (e) Drug release profiles of piroxicam-
loaded THCPSi MPs (black squares) and THCPSi‒lipid vesicles (grey triangles).
Release was performed at 37 ºC in PBS buffer pH 7.4 (solid line) and pH 6 (slashed 
line). The experiments were done in triplicate and the error bars represent the mean ±
s.d. at each timepoint. Copyright © (2014) Royal Chemistry Society, reprinted with 
permission from publication (II).
5.2.2 Cytocompatibility and sustained drug release
Owing to the size of the THCPSi MPs and THCPSi MP‒lipid vesicles, one of the intended
applications for these drug carriers would be the oral delivery of drugs, being advisable to 
test their cytocompatibility with GI tract related cancer cells. The cytotoxicity was then
studied with HT-29 cancer cells and found to be concentration-dependent for both the
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systems (II). However, no statistically significant differences were observed between the 
THCPSi MPs and THCPSi MPs‒lipid vesicles (p ≤ 0.05). Overall, this demonstrated a very 
good cytocompatibility of the developed DDS.
Furthermore, the model drug piroxicam, belonging to the Biopharmaceutical 
Classification class II, i.e., poorly water-soluble drug and with high permeability through 
biological membranes, was loaded in the pores of THCPSi MPs. These were further 
encapsulated in the aqueous core of the lipid vesicles, obtaining a final drug loading degree 
of 19% (w/w). The drug release from both the systems was evaluated in PBS buffer at pH
6 and pH 7.4 (Figure 11e).
The drug release profiles showed that piroxicam-loaded THCPSi MPs released 90% of 
the payload within 50 min. In contrast, lipid-vesicles sustained the release of the piroxicam-
loaded THCPSi MPs, which was dependent on the pH of the release medium. While 100% 
of the drug was released from the THCPSi‒lipid vesicles within 3 h at pH 6, the release was 
further sustained at pH 7.4, being completed within 6 h. The sudden increase in the release 
rate of piroxicam from the THCPSi‒lipid vesicles observed after 200 min. was most likely 
due to the significant vesicle disruption after 4 h, as confirmed by the optical microscope
images (II).
Despite the unfeasibility of loading hydrophobic molecules within the bilayer of ultra-
thin lipid vesicles, this study demonstrated a new approach to achieve a high loading degree 
of a molecule with these characteristics within the aqueous core of the vesicles, due to the 
introduction of THCPSi MPs as the carrier of the drug.
5.3 Microfluidic nanoprecipitation self-assembly of PSi-based 
hybrid nanocomposites with pH-responsive properties (III)
In the third work of this thesis, some of the hurdles that drug nanocarriers present for the 
treatment of tumors were faced, such as the poor water solubility of certain drug molecules,
along with the fast clearance of nanocarriers from blood circulation and the spatially
controlled drug delivery at the tumor site [36, 291]. To address these issues, it was designed 
a smart hybrid nanocomposite consisting of a blend of PEG‒PHIS and PEG‒PLA 
assembled on the surface of SFN-loaded PSi NPs, which was spontaneously formed by 
nanoprecipitation in a flow-focusing microfluidic chip. Importantly, the nanocarrier 
presented PEG on the surface that prevented macrophage recognition likely by avoiding 
protein opsonization.
5.3.1 Characterization
The formation of the PSi‒PC and its properties were monitored by DLS and TEM. Firstly, 
multiangular DLS was used to analyze the angular-dependent size of the PSi‒PC, as well as 
of the empty polymeric NPs. The results showed that the size of both the systems was 
dependent on the angle at which the light scattered detector was set, which suggested that 
the NPs did not present spherical shapes [275]. The size of the NPs was calculated for a 
47
detection angle of at 0°, being for PSi‒PC 260 nm, and for the empty NPs 200 nm, with a
PDI lower than 0.2. Moreover, the size of the PSi NPs measured by DLS was 130 nm. 
Together, the size increment of the PSi‒PC compared to bare PSi NPs and the empty NPs
pointed out to a combination of the last two systems in the PSi‒PC.
The non-spherical shape of the PSi‒PC was further demonstrated by TEM and SEM 
(III). The irregular and porous structure of the PSi NPs could not be identified after the 
formation of the composite, revealing the efficient sealing of the pores of the PSi NPs.
Moreover, it could be observed by TEM that PSi‒PC avoided an extensive aggregation of 
the PSi NPs. SEM images of the PSi‒PC provided a hint about the type of structure formed. 
Small micelle-like structures were observed on the surface of the PSi‒PC, suggesting that 
the structure could be a compound micelle. This structure was formed by small aggregated 
reverse micelles with hydrophilic cores and hydrophobic coronas, interacting by 
hydrophobic forces with the surface of PSi, and further stabilized by a layer of block 
copolymers with their hydrophobic blocks towards the inner reverse micelles and their
hydrophilic blocks towards the aqueous environment.
In addition, the surface zeta-potential of the different NPs was studied, being ?14.8 mV, 
+ 2.8 mV, and ?5 mV for the PSi NPs, compound micelles, and PSi‒PC, respectively. AS 
a result of the assembly of the compound micelle on the surface of PSi NPs, the surface 
negative charges of the latter were compensated by the positive charges of the compound 
micelle, rendering a PSi‒PC with a less negative surface charge.
5.3.2 pH-Triggered drug delivery and cell growth inhibition
PSi‒PC were designed allow the delivery of the drug upon acidification of the environment,
triggered by tumor extracellular microenvironment or intracellular late endosomes or 
lysosomes, which possess typical pH values of 5–6.8 [225, 292]. PEG‒PHIS possesses a
pH-responsive behavior due to the presence of an imidazole ring in each histidine unit of 
the polypeptide, bearing a protonable nitrogen. Under physiological conditions, the 
imidazole remains as the conjugated base of the amine, but upon acidification, the nitrogen 
protonates. Therefore, in the case of PEG‒PHIS, at neutral pH the PHIS is mostly found in 
its unprotonated form, allowing the interaction of PHIS blocks through attractive 
hydrophobic forces, which leads to the self-assembly of the block polymers, rendering 
supramolecular structures [293]. When the pH decreases, PHIS gradually protonates, 
creating repulsive electrostatic forces between the positive charges, and hindering the 
hydrophobic interaction between the PHIS blocks. This leads to the disassembly of the 
structure and dissolution of the polymer. PEG‒PLA was introduced in the structure as a 
modulator, quenching to a certain extent the electrostatic repulsive forces of the protonated 
chains by increasing the hydrophobic interactions, and thus, decreasing the pH value at 
which the electrostatic repulsive forces beat the hydrophobic interactions [294]. Based on 
this, the aim was to achieve pH-triggered drug release from the pores of the PSi NPs upon
the rupture of the polymeric structure assembled on its surface.
SFN, a cytotoxic drug that inhibits cell proliferation and angiogenesis, was loaded in the 
pores of the PSi NPs by an immersion method [64], and further encapsulated into the 
polymeric structure. The drug loading degrees of SFN into PSi NPs and PSi‒PC were 5.8% 
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and 4.9%, respectively. Thereupon, the SFN release profiles from both the nanocarriers and 
the dissolution rate of free SFN were determined in human plasma (pH 7.4) and PBS buffer 
enriched with 10% FBS with pH values of 6.8 and 5.5, in order to mimic the physiological 
tumor microenvironment and the intracellular conditions, respectively (Figure 12a). SFN 
is very poorly soluble in aqueous media, however, in the presence of surfactants, proteins,
or others compounds its solubility can be enhanced. Accordingly, FBS was used to enhance 
the dissolution rate of SFN [121]. Anyhow, due to the remarkably low solubility of SFN,
just 10% of the drug was dissolved in 6 h, for all the media tested. However, SFN-PSi
greatly improved the drug’s dissolution rate up to ~100%. Remarkably, SFN release from 
the PSi‒PC in plasma at pH 7.4 was low (<5%), whereas in PBS‒FBS at pH 6.8 and 5.5 
burst-type release profiles were observed. 
Figure 12 pH-dependent drug release and cell growth inhibition. (a) Dissolution and drug release 
profiles of SFN (solid black line) and SFN-PSi NPs (dashed grey line) and PSi NP‒PC 
(solid grey line). The release was performed in plasma pH 7.4 and PBS enriched with 
10% FBS at pH 6.8 and 5.5. (b) Growth inhibition of PC3MM2 cells incubated with 
SFN (black solid line), SFN-PSi NPs (dashed grey line), and PSi‒PC (solid grey line) 
at pH 7.4 and 5.5 for 24 h. The experiments were done in triplicate and the error bars 
represent the mean ± s.d. at each timepoint. Copyright © (2015) John Wiley & Sons, 
Inc., reprinted with permission from publication (II).
Overall, these experiments confirmed the potential of PSi to significantly increase the 
dissolution rate of SFN, and further highlighted the robustness of the nanocomposite to 
protect the drug inside the structure, preventing major leakage in physiological conditions 
(pH 7.4). To further asses if the pH could trigger the release of SFN from the PSi‒PC and 
allow the drug to exert its therapeutic effect, the cytotoxicity effect of SFN and the SFN-
loaded PSi NPs and PSi‒PC (Figure 12b), was tested by incubating the drug and drug-
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loaded NPs with the metastatic prostate cancer cell line, PC3MM2, at pH 7.4 and 5.5 for 24 
h. The concentration of SFN needed to inhibit the cell population to half (IC50), at both pH 
values was lower than 15 μM. At pH 7.4, SFN-PSi NPs presented an IC50 of ~ 27 μM, while 
SFN-loaded PSi‒PC (SFN-PSi‒PC) did not reach the IC50 within the concentration range 
tested (130 μM). Moreover, the maximum cell growth inhibition achieved by PSi‒PC at pH 
7.4 was 30% and 43% lower than that of SFN-PSi and SFN, respectively. These results 
showed that free SFN was slightly more potent than when loaded into PSi NPs, and that the 
polymeric composite limited the cytotoxic effect of the drug by keeping it locked inside the 
nanocarrier at physiological pH. However, at pH 5.5, the IC50 of the composite was reduced 
to 32 μM, revealing that the acidic conditions triggered the release and the effect of the drug.
In conclusion, SFN-PSi‒PC effectively inhibited the effect of SFN towards PC3MM2 
cells under physiological conditions, while showing greater toxicity under acidic conditions.
However, the free drug was more efficient than the nanocarriers inhibiting cell growth.
Therefore, to really assess the superiority of the nanocomposites over the free drug, the 
combination of pH-triggered drug release and passive targeted delivery of the drug should 
be studied in vivo.
5.3.3. In vitro stealth properties
The efficacy of PEGylation was further evaluated based on the capacity of the composite to 
avoid recognition and clearance by the MPS in vitro. With this aim, RAW 264.7 
macrophage cells were incubated for 3 h in medium enriched with 10% FBS with 
fluorescently labelled PSi NPs and PSi‒PC, and the cellular uptake was studied by confocal
microscopy and flow cytometry (Figure 13a). The confocal results showed greater 
fluorescence density inside the space delimited by the membrane of the macrophages when 
incubated with the fluorescently labelled PSi NPs compared to the composites. These results 
were also supported by the flow cytometry analysis (Figure 13b). Overall, these results 
indicated that 93% of the macrophages internalized the PSi NPs, while just 23% internalized 
the PSi‒PC. In addition, the mean fluorescence intensity (MFI) of the RAW 264.7 cells 
incubated with PSi NPs was four times greater than for the cells incubated with PSi‒PC,
meaning that the macrophages incubated with PSi NPs internalized a greater amount of the
NPs compared to the macrophages incubated with PSi‒PC. Thus, this corroborated that the 
macrophages had less tendency to interact with the PSi‒PC than with bare PSi NPs, most 
likely due to the presence of the PEG (5 kDa) corona on the surface of the nanocomposites. 
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Figure 13 Phagocytosis of PSi NPs and PSi‒PC by RAW 264.7 cells after 3 h incubation at 37 
ºC. (a) Flow cytometry analysis. The histogram represents the percentage of positive 
events at a given fluorescence intensity signal. The negative control, cells without 
treatment, are shown in grey, and the AF 488-labelled PSi NPs and PSi‒PC are shown 
in red and blue, respectively. The table summarizes the MFI value of each event and 
the percentage of positive events. (b) Confocal microscopy analysis. Cell membrane,
in red, was stained with CellMask Deep Red, and the PSi NPs and PSi‒PC, in green, 
were labelled with Tetramethylrhodamine. The first column depicts the negative 
control, cells without treatment. The second and third columns depict cells incubated 
with PSi‒PC and PSi NPs, respectively. Copyright © (2015) John Wiley & Sons, Inc., 
reprinted with permission from publication (II).
5.4 pH-switch nanoprecipitation of polymeric solid NPs for tumor
theranostics (IV)
In the fourth work of this thesis, an advanced targeted and multi-stimuli responsive 
theranostic platform was developed, consisting of SPION NPs encapsulated in a PEG‒PHIS 
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based NP, and further decorated with the tumor homing-peptide iRGD [241]. The developed 
nanoplatform combined intracellularly triggered drug release properties and potential for in
vivo targeting and imaging. In addition, it was performed in this work an in vitro and ex vivo
toxicity assessment, together with the evaluation of the cellular interactions, lysosomal 
escape, and intracellular drug delivery of the developed theranostic NPs.
5.4.1 Characterization and toxicity assessment
The size and surface charge of the NPs was characterized by DLS, and were visualized with
SEM and TEM (IV). The IO@PNP and IO@iRGD-PNP dispersed in 10 mM of HEPES 
(pH 7.5) presented sizes of 210 and 219 nm, PDIs of 0.096 and 0.075, and a surface zeta-
potentials of ?0.23 and ?10 mV, respectively. The presence of PEG on the surface of the 
NPs was responsible for both the neutral surface charge of the nanoparticle and the colloidal 
stabilization by steric hindrance when suspended in a good bulk medium, where PEG is 
well-solvated and prevents interpenetration of chains [295]. The successful encapsulation 
of SPION was observed by TEM. Furthermore, the loading efficiency was found to be 40% 
with a final concentration of 8 μg of SPION per 1 mg of polymer (IV). Importantly, the 
magnetization saturation (Ms) and superparamagnetism of the SPION and the polymer 
encapsulated SPION were characterized by assessing their hysteresis loop (Figure 14a). 
Superparamagnetism is a property of magnetic materials through which their magnetization 
is destabilized by thermal energy. For typical ferromagnets the length scale at which 
superparamagnetism exists has been described to be below ?5–10 nm [296].
Superparamagnetism is a desirable property for NPs to be used for drug delivery, because 
upon removal of the magnetic field the nanoparticles do not present attraction for each other, 
thus avoiding a major driving force for aggregation [296]. In this respect, results 
demonstrated that the superparamagnetism of SPION was preserved after encapsulation in 
the polymeric structure, partially revealed by the hysteresis loop, in which the coercivity 
was negligible, and confirmed by the TEM images of IO@PNP (Figure 14b), where SPION 
was found as single NPs with a size smaller than 10 nm. In addition, the Ms of the SPION 
was found to be 24 Am2/kg, and 38 Am2/kg for IO@PNP. The observed increase in Ms for 
the IO@PNP compared to the SPION, may be attributed to the clustering of SPIONs in the 
polymeric structure [297, 298]. Overall, the Ms displayed by IO@PNP is in the range of 
other magnetic systems found to be useful for magnetic guided therapy in vivo [299, 300].
Furthermore, a prerequisite for the application of NPs in vivo is to demonstrate their 
safety. Therefore, as a preliminary study, the cytotoxicity of the system was assessed using
physiologically-relevant cell types: primary rat liver and kidney cells, and human RBCs.
Primary hepatic and kidney cells are often used for toxicological assessment of chemicals 
due to the capacity of these cells to retain their specialized functions better than by
immortalized cell lines. In addition, these cells are greatly exposed to the NPs, and thus, to 
their toxic effects after i.v. administration in vivo [301]. Accordingly, the viability of these 
cells incubated for 6 h with IO@PNP and IO@iRGD-PNP, in the range of concentrations
of 50 to 500 μg/mL, was studied (Figure 14c). The results showed more than 90% viability 
for the hepatic cells and more than 82% viability for the kidney cells at all the concentrations
tested for both the types of NPs.
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Figure 14 Characterization and in vitro toxicity assessment. (a) Hysteresis loop of SPION and 
IO@PNP. (b) Single IO@PNP with SPION (black dots) that can be identified inside 
the nanoparticle. Scale bar represents 100 nm. (c) Cytotoxicity of IO@PNP and 
IO@iRGD-PNP incubated for 6 h with rat kidney and liver primary cells. Black bars 
represent IO@PNP and grey bars IO@iRGD-PNP. Results were compared with the 
negative controls and the statistical significance levels were set at the probabilities of 
*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. (d, e) Effect of IO@PNP and IO@iRGD-PNP 
over human RBCs. (d) Percentage of RBCs lysed after 1, 4, 6 and 24 h incubated with 
25, 50, 100 and 200 μg/mL of IO@PNP and IO@iRGD-PNP. (e) SEM images of the 
RBCs incubated with 25 and 200 μg/mL of IO@PNP and IO@iRGD-PNP for 4 h. 
Arrows indicate cells that have suffered changes in their morphology. The experiments 
were done in triplicate and the error bars represent the mean ± s.d. at each timepoint.
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RBCs are also very vulnerable to the toxic effects of the NPs administered intravenously, 
as they may suffer changes on the morphology or even lysis, with the consequent release of 
hemoglobin to the blood stream [278, 302]. The intrinsic oxidative nature of hemoglobin 
may cause damage to tissues if not efficiently quenched or metabolized, which is the case 
in severe hemolytic processes [303]. IO@PNP and IO@iRGD-PNP (Figure 14d) showed 
time and concentration-related hemolytic capacity, reaching overall hemolytic rates below 
8.5% for concentrations up to 200 μg/mL and 24 h of incubation, with the exception of 
IO@iRGD-PNP, which after 24 h incubation resulted in hemolytic rates from 12 to 42% for 
the range of concentrations tested. In general, any in vitro hemolytic value <10% is 
considered to be potentially non-hemolytic in vivo, while hemolytic values >25% are 
considered to be potentially hemolytic in vivo [304]. Furthermore, the shorter incubation
times are more representative of the potential harmful effects of i.v. administered NPs, 
because these are distributed and cleared from the bloodstream relatively fast along the time.
Morphologically, some RBCs incubated with both IO@PNP and IO@iRGD-PNP presented 
alterations, although apparently neither concentration- nor NP-dependent. Besides the 
normal discocyte-shaped RBCs, few knizocytes and codocytes were also found (Figure 
14e) [305]. Overall, based on these results, IO@PNP and IO@iRGD-PNP can be considered 
to be safe for their i.v. administration.
5.4.2 iRGD-Mediated cell uptake
The iRGD homing peptide has efficiently demonstrated to mediate the extravasation of 
drugs and NPs from the blood circulation to the tumor site in metastatic cancer models in
vivo through the interaction with αvβ3 and αvβ5 integrins and neuropilin-1, which are
upregulated in angiogenic blood vessels [241, 306], and further spread into the tumor mass.
In addition, these receptors are also expressed by other tumor cell lines and can be 
internalized in these cells through receptor-mediated endocytosis [241, 245]. Based on this, 
the previously prepared IO@PNP were decorated with iRGD and the cellular uptake in vitro
was tested with two relevant cell lines, EA.hy926 and PC3MM2 cells, with the aim to mimic 
the endothelial blood vessels and a metastatic tumor, respectively. Association of the NPs 
was studied by flow cytometry (Figure 15) and subsequently confirmed by confocal
microscopy (Figure 16a). 
For both the cell lines tested, IO@PNP and IO@iRGD-PNP demonstrated extensive and 
concentration-dependent cellular association, with a minimum 80% of the cells containing 
NPs. iRGD decoration of IO@PNP showed modest improvements in the association of the 
NPs to EA.hy926 cells, and no improvements in the case of PC3MM2 cells. Despite the 
promising in vivo tumor homing characteristics of iRGD, these results were already reported 
in an in vitro study; however, the in vitro experiments did not further correlate with the in 
vivo, in the latter case the role of iRGD was more relevant [243], This could be attributed 
to the lack of an unknown protease in cell cultures that cleaves iRGD after its association to 
the cell surface integrins to expose the CendR motif that binds to NRP-1 and would require 
further in vivo analysis [241].
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Figure 15 Cell internalization of IO@PNP and IO@iRGD-PNP incubated with (a) EA.hy926,
and (b) PC3MM2 cells for 3 h at 37 °C. Results show the positive events and median 
fluorescence intensity (MFI). IO@PNP are represented by the black bars and 
IO@iRGD-PNP by the grey bars. Statistical significance was set at the probabilities of 
*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
5.4.3 Lysosomal escape and intracellular drug delivery
Endocyted NPs must escape the endocytic pathway in order to deliver the drug cargo into
the cytoplasm of the cancer cells [307-309]. In this respect, the imidazole groups of PEG‒
PHIS can protonate upon acidification of the endosomes [307], promoting the proton-
sponge effect, and thus, releasing the polymer and the cargo in the cytoplasm of the cells 
[209]. To confirm this, the lysosomes of the cells were labelled (red), and the cells observed 
after 1, 3, and 6 h of incubation with AF 647-labelled IO@PNP and IO@iRGD-PNP 
(IO@AF-PNP and IO@iRGD-AF-PNP, in green) (Figure 16a). These experiments 
revealed that the NPs were predominantly internalized rather than associated to the cell 
membrane of the PC3MM2 cells. Moreover, already after 1 h of incubation, both types of 
NPs were found co-localized within the lysosomes, but also extensively in the cytoplasm, 
demonstrating the capacity of the NPs to escape the lysosomes. The extensive fluorescence 
found in the cytoplasm was most likely owed to the disassembly of the NPs in the 
lysosomes, which were further released to the cytoplasm as block-copolymer chains.
The previous works presented in this thesis (I, II, and III) relied on PSi-base materials
as the carrier for drug cargo, further protected from the premature release using different
approaches. In contrast, in this last work (IV), a polymer-drug conjugate connected through 
an amide bond was designed, and was used to produce NPs. This approach ensures no
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leaking of the drug along the delivery route due to the stable polymeric structure at 
physiological pH and to the chemical stability of the amide bond.
First, it is necessary to demonstrate the in vitro cleavage of the amide bond linking the 
polymer chains to the drug DOX, presumably by the action of the lysosomal enzyme 
cathepsin b, as reported elsewhere [277]. For this, one end of the block-copolymer was 
conjugated to AF, and the other to DOX, rendering IO@AF-PNP-DOX NPs. Therefore, the 
in vitro cleavage of the amide bond linking the polymer chains to the DOX would be 
confirmed by the absence of co-localization of both the signals intracellularly. Thus, 
PC3MM2 cells were incubated with IO@AF-PNP-DOX and observed by confocal 
microscopy after 1, 3, 6, 10, and 24 h (Figure 16b). It was found that DOX and AF were 
mostly not co-localized, being the fluorescent signal of AF localized in the cytoplasm of the 
cells and DOX co-localized with DAPI in the nuclei, sparingly after 1 h of incubation and 
extensively after 3 h of incubation, in particular in the nucleoli. After 6 and 10 h of 
incubation, exocytic vesicles were found, in which the fluorescent signals coming from 
exocyted genetic material (stained with DAPI) and DOX, were co-localized. After 24 h of 
incubation, the damage to the cell culture was undisguised, cell debris, exocytic vesicles, 
apoptotic, and living cells, prominently containing DOX co-localized with their nucleoli, 
were found.
In general, these results pointed out that when the IO@AF-PNP-DOX NPs were 
endocyted and reached the lysosomes they protonated and disassembled due to the acidic 
pH of this organelle [307], possibly allowing the action of the lysosomal enzyme cathepsin-
b on the amide bonds [309], which cleaved the DOX from the structure, while creating 
internal osmotic pressure that eventually caused the burst of the lysosome and cytosolic 
release of the drug [307]. Thereafter, free DOX translocated into the nucleus of the cells 
[310] and seemingly accumulated in their nucleoli. This observation is in agreement with 
previous reports about the preferential location of DOX in the nucleolus and the interaction 
of DOX with both DNA and RNA [311, 312]. These experiments demonstrated in vitro the 
cleavage of the amide bond between DOX and the block copolymer of the NPs, and the 
translocation of the drug to the nucleus of the cells, which opens up the door for further 
mechanistic exploration of the DOX internalization and release from these nanocarriers in 
this fashion.
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Figure 16 Intracellular trafficking and drug delivery. (a) Lysosomal escape of IO@PNP and 
IO@iRGD-PNP incubated with PC3MM2 cells for 1 h. Lysosomes were stained with 
LysoTracker® Red (red) and IO@PNP were labelled with AF 647 (green). Co-localized 
lysosomes and IO@PNP appear in yellow. (b) Confocal fluorescence microscope
images of the fate of IO@PNP-DOX in PC3MM2 cells at different incubation time 
points. The nuclei of the cells was stained with DAPI (blue), DOX-IO@PNP were 
labelled with AF 647 (green), and DOX is shown in red. Co-localized DOX with DAPI 
and AF 647 appears in pink and yellow, respectively.
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5.4.4 In vitro cell growth inhibition
To confirm the successful delivery of DOX intracellularly, the cytotoxicity of DOX 
administered in its free base form and conjugated to the NPs after 24 h incubation, was 
evaluated (Figure 17).
Figure 17 Cytotoxicity of DOX, IO@PNP, IO@PNP-DOX, IO@iRGD-PNP, and IO@iRGD-
PNP-DOX incubated with PC3MM2 cells for 24 h. The experiments were done in 
triplicate and the error bars represent the mean ± s.d. at each timepoint. Statistical 
significance levels were set at probabilities of *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001.
For the incubation time and concentration range tested of DOX and its polymer-
conjugated form, 1 to 4 μM, DOX free base did not present cytotoxic effects, while 
IO@PNP and the iRGD decorated NP presented certain cytotoxicity. The toxicity of the 
NPs was likely due the polycationic nature of PHIS, which, by promoting the proton-sponge 
mechanism, also causes the spillage of the lysosomal content and triggering of intracellular 
Ca2+ release leading to some toxicity [313]. However, IO@PNP-DOX showed augmented 
cytotoxicity compared to the free drug and the NPs, 45 and 14% greater on average, 
respectively. Likewise, IO@iRGD-PNP-DOX demonstrated to enhance the cytotoxic effect 
of DOX free base and the NPs, 31 and 12%, on average, respectively. The enhanced 
cytotoxicity of the DOX-NP conjugates can be ascribed to a combination of the inherent 
toxicity of the IO@PNP and the efficient intracellular delivery of the drug, which might be 
hindered for the free base form of the drug due to its poor aqueous solubility. The finding 
confirmed the possibility of using this type of polymer-drug conjugate NPs as a vehicle for 
intracellular delivery of drugs.
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6 Conclusions
In this dissertation, lipids and polymers in combination with PSi particles, and a polymer-
drug conjugate, were utilized to fabricate advanced DDS for the loading of hydrophilic and 
hydrophobic drugs in order to achieve sustained or triggered drug release and to improve 
the dissolution properties of poorly aqueous soluble drugs. In addition, the potential of the 
DDS for tumor therapy was evaluated in vitro.
In the first study, it was investigated the loading and release properties of PSi MPs and 
PSi MPs encapsulated into a solid lipid matrix, using model drugs with different solubility 
profiles. The microcomposites, produced by single emulsion droplet-based microfluidics,
demonstrated to sustain the release of hydrophilic and hydrophobic drugs, reduce the initial 
‘burst release’ observed for bare PSi, and also to modify the surface properties of PSi, 
making it less hydrophobic and reducing its cytotoxicity.
The second study explored, the encapsulation of a hydrophobic drug molecule within 
the aqueous core of lipid vesicles aided by PSi MPs. Piroxicam-loaded PSi?lipid vesicles
were produced by double emulsion droplet-based microfluidics in a highly reliable, 
reproducible, and efficient manner; and were capable of sustaining the release of piroxicam, 
particularly at pH 7.4.
In the third study, a smart hybrid nanocomposite was developed for antitumoral 
applications with triggered release and stealth properties. The nanocomposite, produced by 
flow-focusing microfluidics nanoprecipitation, consisted of a pH-sensitive polymeric 
compound micelle assembled on the surface of PSi NPs loaded with the hydrophobic drug 
SFN. The release of SFN was successfully prevented in physiological conditions (pH 7.4) 
while fast release was observed in acidic conditions. Accordingly, the SFN-loaded 
nanocomposite evidenced a pH-dependent cell growth inhibition capacity of a prostate 
cancer cell line, resulting in more cell death at pH 5.5 than at pH 7.4, revealing the potential 
of the developed nanocomposite of reducing the drugs’ unspecific effect. Furthermore, the 
nanocomposite presented limited interaction with macrophages, indicating the potential of
the DDS for prolonged blood circulation time. 
In the fourth study, a targeted theranostic DDS was developed with multi-stimuli 
responsive properties to magnetic field and pH, consisting of a polymeric-drug conjugate 
NP, containing encapsulated SPION, and decorated with a tumor homing-peptide, iRGD.
The DDS was fabricated by pH-switch nanoprecipitation in organic-free solvents, ideal for 
further biomedical applications. The DDS demonstrated reduced cytotoxicity and hemolytic 
effects. Moreover, the association of DDS with endothelial cells was extensive, and was 
moderately enhanced by iRGD. The DDS demonstrated efficient lysosomal escape in vitro,
likely due to the proton-sponge effect exerted by the pH-sensitive polymer. In addition, the 
amide bond linking the polymer to the anticancer drug DOX was cleaved intracellularly, 
allowing the drug to translocate into the nucleus, and improving, in this fashion, the 
performance of the drug.
In conclusion, the developed hybrid micro- and nano-systems in this thesis represent a 
novel contribution to the field of drug delivery, in particular regarding PSi as a platform for
advanced DDS. Moreover, the DDS systems evaluated in vitro for antitumoral applications 
hold great potential for their further in vivo assessment.
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